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ABSTRACT
CHARACTERIZATION OF HIGHLY HETEROGENEOUS HEPARIN-PROTEIN
COMPLEXES USING NOVEL MASS SPECTROMETRY-BASED APPROACHES
SEPTEMBER 2017
YUNLONG ZHAO, B.S., NANKAI UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Igor A. Kaltashov
Heparin-like glycosaminoglycan (GAG) is a family of polysaccharide involved in
variety of physiological processes. They have potentials to interact with a broad
range of proteins and many of them hold crucial values in regulation of protein
functions. My dissertation addresses the significance and challenges in the field of
heparin-mediated studies, with a focus on the questions in biological and analytical
aspects, which are largely hindered by the structural heterogeneity and function
diversity of heparin. My dissertation reports the efforts I made in the past few years
with respect to the development of novel analytical strategies based on a
combination of mass spectrometry, ion-mobility, gas-phase chemistry and
chromatography,

with

success

in

characterizing

protein-GAG

interacting

stoichiometry and deciphering the structural code related to protein-GAG affinity.
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CHAPTER 1
HEPARIN-INOVOLED RESEARCH OBJECTIVES AND BACKGROUND

1.1 Heparin and Heparin-Related Scientific Questions
1.1.1 Structure and Functions of Heparin-Like Glycosaminoglycan
Glycosaminoglycan is a big family of linear polysaccharide featured by
repetitive units containing amino sugar and uronic acid sugar. Heparin and heparan
sulfate both belongs to the same “genus” in glycosaminoglycan (GAG) family, which
are ubiquitously found in human body. I borrow the term from taxonomy because
both heparin and heparan sulfate have high similarity in terms of the structure and
physical properties. The repetitive disaccharide unit of heparin or heparan sulfate
consists of a glucosamine and a glucuronic acid or iduronic acid (which differ from
each other with respect to the chirality of C5) (Figure 1-1). Sequence polydispersity
arises from the biosynthesis of heparin-like GAGs, in which enzymatically controlled
modifications of precursor linear polysaccharides lead to tremendous variability in
the levels and patterns of O- and N-sulfation and deacetylation. Interestingly,
although we believe these two species of GAG can do exactly the same thing in the
human body because they can interact with broad range of proteins through the
sulfate groups and the basic groups in proteins, they actually have very different
physiology-relevant emphases. Heparan sulfate is synthesized in many cells and has
diverse functions in physiology ranging from tissue development to immune
regulation1,2 and is associated with many diseases such as cancer3 and
neurodegenerative diseases4,5. For example, matured fibroblast cells present

1

heparan sulfate in the form of proteoglycans on the extracellular matrix and it can
regulate the function of fibroblast growth factor family, facilitating the affinity to
fibroblast growth factor receptors6,7. In contrast, heparin is only synthesized in the
mast cells, so it dominantly serves in blood as a coagulant regulator8-11. Therefore,
heparan sulfate has larger variety of the chain lengths (for anchoring with matrix
proteins); and heparin contains higher degrees of sulfation (for effective action on
coagulant factors). It needs to be clarified here that we often use the term “heparin”
to represent all heparin-like GAGs or use the heparin molecules of higher
modification variety (which is cheaper as well) as a model molecule for developing
analytical methods that can be applied for other heparin-like GAGs or other
heterogeneous polyanions.

1.1.2 Heparin-Like GAG as Therapeutic and Medication
1.1.2.1 Heparin as Anticoagulant Reagents
Since the mystery among heparin, antithrombin and factor Xa has gradually
been unveiled, heparin became one of the most effective anticoagulant reagents
used for treatment of thrombosis or supplied in the circumstance when blood
clotting needs to be prevented, such as surgical operations or intravenous therapies.
Although heparin as an conventional active pharmaceutical ingredient (API) has
been used for decades, the downstream demand of it is still growing.12 Effective
heparin-based therapeutics includes full-length unfractionated heparin (UFH), the
enzymatic degraded low-molecular-weight heparin (LMWH) and the synthetic
pentasaccharides designed (commercially available as ArixtraTM) with different
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efficacy and safety based on clinical data13-17. The coagulant cascade is initiated by
activation of coagulant factors via proenzyme cleavage and terminated by
interaction with antithrombin (AT), an inhibitor to many coagulant factors (such as
thrombin or factor Xa). The presence of heparin will dramatically facilitate the
inhibitory function of AT. The mechanism of the heparin-mediated factor Xa or
thrombin inhibition is still embroiled in a controversy between structural biologists
and biophysicists. From the prospective of structural biology, heparin binding
allosterically induces the conformational change of AT, making its inhibitory loop
accessible to factor Xa/thrombin, followed by a typical serpin-protease mechanism.
This point is supported by X-ray studies and will be illustrated in more detail in
section 2.1. And biophysicists highlight the role of heparin as a bridge to either
stabilize the transient complex formed by AT and factor Xa/thrombin or improve
the chance of collision between the two proteins by reducing the degree of
diffusional freedom.
Regardless of which mechanism is accepted, it has been established that
there is positive relevance between heparin-binding affinity and the anticoagulant
effects. And the binding affinity of heparin to proteins under physiological
conditions (i.e. neutral pH and modest ionic strength) is affected by many factors
including the length of heparinoids and the degree of sulfation. Although it is still a
question that whether all heparin-binding proteins require a heparin motif
consisting in a specific sulfation pattern (assuming some of interactions may just
rely on a non-specific electrostatic interaction), for AT a particular sulfation pattern
within the binding region is definitely required for retrieving the maximum binding
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affinity. Relevant studies have shown that a special 3-O-sulfation at one glucosamine
unit are critical to modulating the binding affinity18,19 but its presence is rare in
naturally-occurring heparin samples, which dominantly consist of glucosamine with
6-O-sulfation, 2-N-sulfation and iduronic acid with 2-O-sulfation. That explains why
only 30% of heparin can bind to AT and no AT-binding affinity has been observed in
heparan sulfate, the latter containing even fewer sulfation sites. The synthetic
strategy to produce the heparin oligosaccharides with unique structure and
sequence (e.g. the pentasaccharide) has been carried on to generate species with
high anticoagulant efficacy.20-22

1.1.2.2 Heparin-Based Therapeutics Deliver System
Although the function and therapeutic value of heparin mainly resides in the
anticoagulant effect through interaction with AT, many other proteins with clinical
values have the potential to bind to heparin. Taking advantage of the functional
diversity of heparan sulfate and synthetic chemistry, we can always design and build
heparin-based materials to trap therapeutic proteins or nucleic acids. Heparinbased delivery systems feature high capacity of client protein and excellent
degradability. One important area where a heparin-based delivery system holds
enormous promise is in regenerative medicine, where their potential for controlled
growth factor delivery is being actively explored.23-25 One of the possible designs of
a nanogel is to utilize heparin chains electrostatically attached to polycationic
segments of elastin-like polypeptide for loading of growth factors and morphogens
with

subsequent

delivery

to

the

damaged
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tissue

(such

as

the

poly-

lysine/heparin/payload protein complex highlighted in Figure 1-2). In addition,
understanding the ability of heparin-like GAGs to sequester and release growth
factors will translate to advances in the design of tissue engineering scaffolds. On
the other hand, developing novel heparin-based nanomaterials with advanced
properties (such as temperature-sensitive control) expands the applications of
heparin in the field of therapeutics.26,27

1.1.3 Challenges of Heparin-Like GAG in Analytical Chemistry
One of the most highly desired objectives in the field of heparin-mediated
protein regulation is to understand and define the structure/function relationship
and finally decipher the sulfation code within the protein-heparin interactome.
However, the structural diversity exhibited in heparin-like GAG makes this objective
difficult to achieve even compared to the complex paradigm of protein-protein
interactions. The structures of proteins are usually tightly controlled at the genetic
level, and enzymatic modifications (such as phosphorylation, which plays roles of
on/off switches in signaling) are typically limited to one (or a handful) per
polypeptide chain. Contrary to this, heparin-like GAGs exhibit a dramatically higher
level of structural diversity, and the segments conferring affinity to specific targets
frequently are not well defined. Nevertheless, extensive efforts have been made
searching for specific and precisely defined GAG sequences capable of recognizing
protein targets with high affinity.28 This early success in the discovery of ArixtraTM
inspired numerous subsequent searches for well-defined recognition sites in other
GAG-interacting proteins. Many of the more recent studies have led to a more
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nuanced view of GAG structural motifs and their affinity for specific proteins (e.g., a
set of sulfate groups at strategic locations as opposed to a well-defined chemical
structure29.
Besides the uncertainty in the mechanism of protein modulation, the
heterogeneity in samples of heparin-like GAG also brings about challenge in
analytical strategy itself. Countless modifications make the simple task such as mass
measurement of protein-GAG complexes impossible. Measuring the mass would
help determine the binding stoichiometry, evaluate the binding affinity and
characterize the structure. The general ideas to overcome this challenge are i) to use
a synthetic GAG with pure sequences for numerous activity tests and the
mechanistic studies or ii) to seek better separation strategies or powerful analytical
tools, which are reviewed in the following sections.

1.2 A Map of Prevailing Arsenals for Studying Heparin-Protein Interaction
In this section, I enumerate several popular tools, which have been used in
heparin-related studies for decades.

1.2.1 Traditional Structural Biology Strategies
The mechanism of a modulator (protein or other ligand) affecting protein
function is mirrored by its impact on protein structure. Traditional tools such as Xray crystallography and NMR has been successful in answering this type of
questions by defining localization of ligand-binding sites and enabling structural
comparisons. High resolution structures are achieved by crystalizing the ligandbond protein to fix a snapshot of the all-atom coordination and the electron density
6

map (including the intensity and phasing) generated based on the X-ray diffraction
data is used to build up the structural model. This approach has been performed in
order to completely understand how heparin-like GAG regulates the function of
proteins. And in all of these cases, a synthetic oligosaccharide was utilized. The
heparin-binding site of AT and the allosteric activation model in the inhibition of
Factor Xa was also acquired using this approach,8,30 where a fully sulfated, pure
pentasaccharide was used. From the crystal structures we clearly see that AT
activation upon pentasaccharide binding is the crucial step for Xa inhibition. This
mechanism agrees with the earlier discovery that the ternary complex of heparinAT-Xa does not require a direct interaction between heparin and the protease Xa16,
while the ternary complex formed by AT-heparin-thrombin does. The structures of
the ternary complex were solved by two groups in the same year31,32; they both used
mimetic heparin polysaccharide containing two negative charged domains, which
enabled them to bind AT and thrombin individually. As another giant family of
heparin-binding proteins, the fibroblast growth factors (FGF) initiate signaling
related to cell proliferation and differentiation through the binding to the fibroblast
growth factor receptor (FGFR), which can be facilitated by the mediation of heparan
sulfate. A series of FGF•FGFR structures in the presence or absence of heparin
oligomer were resolved for different protein subspecies33-35. Some dynamic regions
(e.g. the GAG units unbound or nonspecifically bound to the protein) were likely
missing from the electron density map. Nevertheless, crystallography is still the
most reliable approach to understanding the role of certain modification pattern in
protein binding (by tracking the hydrogen bonds and salt bridges). Compared to
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crystallography,

NMR

can

generate

structural

models

embracing

more

kinetic/dynamic information. In solution, protein structure in the presence of GAG
can also be resolved using NMR, which provides some critical insights regarding
heparin-mediated FGF-FGFR interaction and thrombosis.36-38 It should be noted,
that structural modeling can be interpreted in an unbiased fashion only if the
relationship between protein function and the structural variety of heparin-like GAG
has been elucidated through other empirical and experimental approaches. It is
critical to choose an appropriate binding element to generate a snapshot that may
also represent the scenarios for other related binders.

1.2.2 Physical Chemistry Strategies
The hypothesis that the functional effects of heparin arise from specific
interaction between positive residues of proteins and sulfate groups of heparin-like
GAGs can be demonstrated using model saccharides and solving the structure. If
true, the redundant sulfate-containing disaccharide may not participate in the
protein regulation based in the “key-to-lock” model. Physical chemistry fills the gap
caused by a universal electrostatic interaction with the polyanion-particle
interaction model emphasizing the roles of charge density in binding affinity and
many heparin-mediated effects, such as protein aggregation39,40. This approach
provides better insights regarding the universal basis of heparin/protein interaction
in solution. Many tools for biophysical chemistry studies have also been used
including capillary electrophoresis (for measurement of mobility), light scattering
techniques (for measurement of size distribution) and isothermal calorimetric
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titration (for measurement of binding affinity). These techniques are usually
tolerant to the structural variety to some extent and can deal with heterogeneous
sample directly without extra separation. One fruit we have harvested from this
area is the knowledge that binding affinity (perhaps contributed by non-specific
electrostatic interaction) is affected by environmental factors including pH and ionic
strength, which is valuable information for us in choosing a condition in order to
strengthen the global binding affinity and/or minimize non-specific binding.

1.2.3 Mass Spectrometry-Based Strategies
Mass spectrometry holds several advantages when being applied to the
heparin-related analysis: i) moieties rich in sulfate provide numerous negative
charges (in the electrospray source) and enhances the detection of the ions (in the
negative ion mode); ii) all successfully ionized heparin molecules can be displayed
simultaneously in a mass spectrum and those peaks representing different masses
can be distinguished as long as the resolving power and dynamic range of the mass
analyzer can tolerate and accurately reflect the heterogeneity in the sample. Mass
spectrometry is a perfect analytical tool for many applications including GAG
sequence mapping, protein epitope mapping and GAG-bound protein structure
characterization.

1.2.3.1 Mass Spectrometry-Based “Proteomics”
The robustness of mass spectrometry is tightly associated with the most
straightforward tasks: to characterize the identity of GAG molecules in terms of the
mass, structure and sometimes the abundance in the background of many other
9

species. The applications for this technology may range from completely profiling
heparin-like GAG in naturally-occurring samples to identifying the heparin segment
interacting with partner proteins. The area of glycosaminoglycanomics aiming at
analyzing the GAG sample extracted from different tissues, cell types and individuals
borrows the following means from regime of proteomics.
(1) Similar to the “bottom-up” strategy in proteomics, unfractionated
heparin-like GAGs need to be digested to small segments in order to be analyzed
effectively41. The segments can be further restrained if the purpose is to screen the
segments that can tightly bind to a protein. The digested mixture as a library often
passes through a protein-immobilized column.
(2) The high-throughput analysis relies on a LC separation prior to the MS
analysis. Similar to the platform of proteomics, the LC separation can be combined
with MS in an online fashion42. The types of separation for GAG can be RPC, HILIC
and SEC.
(3) Deconvolution of the spectra is based on database search for a structural
assignment at MS level. Recently, the Zaia group utilized an optimized online SECMS approach to analyze a GAG sample and successfully identified species with the
chain length up to 30 saccharide units.43
(4) Identification of GAG segments can be done at the MS/MS level to fulfill
advanced ion monitoring and structural analysis. For example, Linhardt and his
collaborators in China developed a LC-MRM method to quantitatively analyze
disaccharide from cell culture. Like proteomics employing MS/MS for peptide
sequencing, cross-ring fragmentation of GAG can allow us to localize the
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modifications. The Amster group introduced electron-detached dissociation (EDD)
technique into this field, which can generate a huge number of fragment ions
consisting in the cross-ring fragmentations and does not induce sulfate shedding.44
However, EDD has to be carried using an incredibly long acquisition time and hence
it is impossible to run with online LC separation. The Sharp group recently
developed a CID-based online LC-MS/MS platform where the labile sulfate groups
for CID are derived to isotopic-labeled acetylated group during the sample
preparation step45.

1.2.3.2 Native Mass Spectrometry for Protein-GAG Complex
In native mass spectrometry, the solution conformation and non-covalent
structure of protein complexes can be maintained to a large extent. One of the
merits of using native mass spectrometry for characterization of protein-GAG
complex in the gas-phase is that the electrostatic interactions between protein and
GAG are strengthened and hence the complexes can withstand harsh desolvation
conditions. An intrinsic drawback of native mass spectrometry is the modest mass
accuracy in the high m/z regions, so it usually hinders native mass spectrometry
being primarily chosen for identification of the ions with significant mass variation.
However modern mass spectrometer (e.g. FT-ICR) dramatically improves the
resolving power and mass accuracy for a wide range of heterogeneous analytes. For
example, AT was incubated with a combinatorial hexasaccharide library and was
analyzed in a manner of intact complexes under the native condition. As a result,
peaks represent AT interacting with different dp6 members displayed in the
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spectrum and have adequate resolution to determine the number of sulfate groups
and ammonium adduct. A semi-quantitation was achieved based on the peak
areas46.
Another potential value of native mass spectrometry is that the ions with
near-native structure can be further manipulated in the gas phase, which reflects
meaningful information regarding the structure and stability. In another work
related to AT interacting with pentasaccharides, the collisional cross section (i.e. the
average projection area of a tumbling ion) of native ion of complex was estimated
using ion-mobility spectrometry as a supplemental measurement of native mass
spectrometry.47

1.3 Future Directions: State-of-Art Mass Spectrometry-Based Techniques
Although current tools described in previous sections hold the keys to vast
array of heparin-related questions, the limiations of those techniques present
analytical challenges caused by heterogeneous structure and diverse function of
heparin-like GAG. To push the boundaries toward the better elucidation of
structure/diversity relationship, I will explore some emerging mass spectrometrybased techniques in this dissertation. The mainly relevant techniques are discussed
as following, which aim at increasing a dimension of separation an may be
promising to solve heterogeneity-related problems.

1.3.1 Ion-Mobility Spectrometry Mass Spectrometry
In traveling wave ion-mobility spectrometry, the gas-phase mobility of an ion
is measured based on its arrival time when passing through a plate-stacking cell in
12

the buffering gas. Mobility of an ion can be converted to CCS, which is a reflection of
the particle size and structural features. It is still controversial whether the
structural model predicted based on measured CCS values and MD simulations can
be trusted. Nevertheless, ion-mobility spectrometry is absolutely a powerful
separation tool even for the molecules with small structural differences.
Interestingly, ion-mobility measurements are enabled for both precursor ions and
product ions, in a MS/MS experiment. Li’s group has reported work involving IMS to
locate a single epimeric amino acid within a peptide by comparing arrival times for
fragment ions48.
For heparin and heparin-protein complexes, structural variety may lead to a
MS peak convolution. The ion-mobility separation will potentially increase the
resolution by increasing an extra dimension of separation. This feature will be
demonstrated and reiterated in following chapters (Chapter 2 through 4).

1.3.2 Novel Online LC-Native MS for Protein complexes
Native MS can be combined with size exclusion chromatography (SEC) and
ion exchange chromatography (IXC) in an online fashion. Our group is one of the
pioneers to explore the feasibility of SEC-MS49 and IXC-MS50 and its potential
applications. This technique has now drawn quite a lot of attention from many
groups in industry. It can be used to characterize highly heterogeneous sample such
as those proteins containing combinations of post-translational modifications.
It has been reviewed previously that SEC-MS is a perfect tool for highthroughput profiling low-molecular-weight heparin, because the species with
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different chain length are retained on the column for different time and can be
identified individually. This feature should work for protein-heparin complex as
well under the native condition in order to reduce the peak convolution. Online SECnative MS will be an important tool for achieving our goal in the fourth chapter.

1.3.3 Gas-phase chemistry for manipulation of gaseous ions
The last approach to enhance the analytical dimensions is the use of
quadrupole. In another words, gas-phase chemistry including collision-induced
activation and electron-transfer-induced limited charge reduction can be applied on
a mass-selected population. And the latter has been verified to be promising in
determining the mass for heterogeneous protein systems.51 The most intriguing
aspect of this is that the gas-phase chemistry can be combined with other two
separation-tools mentioned above and give rise to a three-dimensional analytical
platform. The combination of charge-reduced or activated ions and ion-mobility
separation will be reiterated in Chapter 2,3,4.
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Figure 1-1. The wide size range (1-50 kDa) and enormous diversity of
sulfation patterns epitomize the extreme structural heterogeneity of heparin
and related GAGs
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Figure 1-2. Schematic representation of a nanogel construct utilizing heparinbased linkers to load growth factors and morphogens (labeled as HBPs,
heparinbinding proteins) for delivery to tissues
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CHAPTER 2
INTERACTIONS OF INTACT UNFRACTIONATED HEPARIN WITH ITS CLIENT
PROTEINS CAN BE PROBED DIRECTLY USING NATIVE ELECTROSPRAY
IONIZATION MASS SPECTROMETRY*

2.1 Introduction
Glycosaminoglycans (GAGs) are ubiquitous linear polysaccharides that carry
out diverse functions in the human body,1 with heparin being perhaps one of the
best known GAGs due to its widespread use in medicine as an anticoagulant.2 In
addition to its critical involvement in the blood coagulation cascade, heparin (as
well as its next-of-kin heparan sulfate3) possesses a broad range of other clinically
relevant properties.4,5 Despite the widely acknowledged therapeutic potential of
heparin and heparin-like GAGs in clinical fields ranging from oncology to
neurodegenerative

diseases

to

tissue

engineering,6-10

their

use

remains

disappointingly limited outside of the anticoagulant field.11 One of the major reasons
for that is the extreme structural heterogeneity of heparin, which makes it very
difficult to decipher the molecular mechanisms of its interaction with nearly half-athousand proteins comprising GAG interactome.12 Even the mundane task of
determining the composition and binding stoichiometry of heparin/protein
complexes remains presently unattainable (unless intact heparin is substituted with
relatively homogeneous short fragments13-16 or synthetic mimetics17). Sequence
polydispersity of heparin and related GAGs arises from their biosynthesis, in which
This chapter is an authorized reprint of the article published by Zhao, et al. in
Analytical Chemistry 88 1711-1718 (2016).
*
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enzymatically-controlled modifications of precursor linear polysaccharides lead to
truly intimidating variability in the levels and patterns of O- and N-sulfation and
deacetylation. These countless modification patterns (which appear to be stochastic,
but are in fact exquisitely regulated and biofunctional), as well as the chain length
variation, present a truly Herculean task vis-a-vis analytical characterization of
heparin and its interaction with client proteins.
Among the many experimental techniques used in biophysics and structural
biology to probe biopolymer interactions, native electrospray ionization mass
spectrometry (ESI MS)18-20 stands out as a versatile tool that is not limited by the
physical size of the non-covalent assemblies and is capable of observing multiple
species in solution as long as the distinction can be made on the basis of mass.
However, in a case of highly heterogeneous samples native ESI MS (as well as ESI MS
measurements carried out under denaturing conditions) fail to provide meaningful
information due to extensive overlap of ionic peaks corresponding to species with
different masses but similar or indeed identical m/z values; in extreme cases these
overlaps may give rise to a continuum distribution of ionic signal without any
discernable features.21 Historically, complexity reduction of ESI mass spectra of
heterogeneous

samples

was

achieved

by

introducing

a

separation

(chromatographic) step into the workflow,22 which requires the use of nondenaturing chromatography (such as size exclusion), if the separation step is to be
combined with native ESI MS.23 Instead of (or sometimes in addition to) introducing
a solution-phase separation step, ion mobility can provide an orthogonal separation
dimension in the gas phase to aid MS analysis of complex samples.24,25
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Interpretation of highly congested mass spectra can also be aided by using ultrahigh resolution mass analyzers capable of resolving even very closely spaced ionic
peaks,26 although this approach is typically used for relatively low-molecular weight
analytes, while its applications in the analysis of heterogeneous biopolymers remain
limited. Finally, spectral congestion can be frequently brought to an acceptable level
by reducing the charge states of biopolymer ions via e.g. proton transfer reactions in
the gas phase.27
Recently, we introduced an approach that combines complexity reduction
(mass-selection of a narrow distribution of ionic species from a heterogeneous
mixture) and either electron transfer to or electron capture by the selected ions
without subsequent dissociation to induce partial reduction of the ionic charge.28
The resulting spectra are easy to interpret, leading to correct mass assignment for
biopolymer assemblies as large as 0.5 MDa.29 Using the electron-based charge
reduction schemes as opposed to proton-transfer reactions allows this approach to
be applied to macromolecular ions in which the majority of cationizing agents are
not protons (e.g., synthetic polymers and nanoparticles). Since the gas-phase GAG
polycation formation usually proceeds via alkali metal30,31 or ammonium adduct
formation,15 electron-based charge reduction should also be well-suited for heparin
and its complexes with the client proteins. In the present work we use this approach
to obtain meaningful information on complexes formed by intact unfractionated
heparin with a paradigmatic heparin-binding protein, antithrombin-III (AT).
Complexes of multiple stoichiometries (up to three AT molecules per single heparin
chain) are detected alongside free (unbound heparin). We also demonstrate that a
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combination of this technique with ion mobility separation in the gas phase allows
the total analysis time to be decreased dramatically. The ability to detect distinct
heparin/protein complexes demonstrated in this work expands the reach of native
ESI MS into the field where analytical options have been very limited so far. This
development will undoubtedly have a significant impact not only by catalyzing the
studies of the mechanisms governing the interactions of heparin-like GAGs with
their client proteins, but also by assisting the design of new and effective drug
delivery systems utilizing heparin as a scaffold in areas ranging from oncology to
tissue regeneration.32-34

2.2 Experimental
2.2.1 Materials
Porcine heparin (from mast cells) was purchased from Sigma-Aldrich
Chemical Company (St. Louis, MO) and used without any purification, fractionation
or enzymatic treatment. High heparin-affinity fraction of antithrombin-III (AT) was
a generous gift from Professor Paul Dubin (UMass-Amherst). All solvents, buffers
and salts were of analytical grade or higher. The stock heparin solution was
prepared by directly dissolving weighed powder in water and the stock protein
solution was cleaned via buffer exchanging into 30 mM solution of ammonium
acetate using ultrafiltration. The heparin/AT mixture was prepared immediately
before the MS analysis without extended incubation. The final concentrations of AT
and heparin were 0.025 mg/mL and 0.03 mg/mL, respectively.
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2.2.2 Methods
All MS and ion mobility measurements were carried out with a Synapt G2-Si
HDMS (Waters Corp., Milford, MA) mass spectrometer equipped with a nanospray
ionization source. To minimize collisional activation of ions transferrin the ESI
interface region, the following parameters were kept at minimal values: sampling
cone voltage, trap CE, trap DC bias and transfer CE. Ion selection prior to limited
charge reduction in the trap was carried out by setting quadruple parameters for
different width of ion transmission window: LM resolution, 2 – 4; HM resolution, 15;
and offset voltage, 0. To trigger electron transfer reactions, the trap wave height was
set at 0.5 V. ETD recharging current was also optimized (typically 8 – 20 A) for
sufficient intensity of charge-reduced species. Post-acquisition processing of MS and
IMS data was carried out using MassLynx 4.1 and DriftScope 2.6, respectively
(Waters Corp., Milford, MA). Curve fitting was done using OriginPro (Origin Labs,
Northampton, MA).

2.3 Results and Discussion
2.3.1 Characterization of protein/heparin complexes using “traditional” native
ESI MS and/or ion mobility spectroscopy
Native ESI MS provides an elegant way to monitor interactions of short and
relatively homogeneous heparinoids with proteins;13-17 however, application of this
technique to larger systems (such as intact heparin) is not straightforward. Figure
2-1 shows native ESI mass spectra of AT in heparin-free solution and AT/heparin
mixture. The mass spectrum of heparin-free AT contains contributions from two
glycoforms, which are commonly referred to as α- and β-AT (molecular weights 57.9
25

and 55.7 kDa, respectively),35,36 with the latter accounting for over 90% of the total
ionic signal. The mass spectrum of the AT/heparin mixture displays abundant ionic
signal, while at the same time showing that the signal of free (unbound) AT is nearly
eliminated, suggesting that strong binding takes place between the protein
molecules and the GAG chains. However, the ionic signal above m/z 4,000 is a
completely unresolved continuum distribution that spans several thousand m/z
units. Even though the distribution is not monotonic, and some features can be
discerned, it is impossible to obtain any meaningful information related to the ionic
masses. Likewise, IMS analysis of the AT/heparin mixture reveals the presence of
several semi-distinct (partially overlapping) ionic populations (see Figure 2-S1 in),
but the additional separation afforded by the mobility measurements in the gas
phase clearly is not sufficient for obtaining interpretable IM-MS patters from which
the masses of putative AT/heparin complexes could be deduced.

2.3.2 Limited charge reduction of heparin polycations in the gas phase is
accompanied only by minimal ion dissociation
We approached the task of measuring the masses of AT/heparin complexes
initially by isolating relatively narrow ionic populations in the gas phase followed by
their charge reduction using electron transfer reactions, a technique initially tested
on extensively glycosylated proteins,28 and later applied to large protein
complexes29 and aggregates.37 Electron-driven charge reduction of the polycationic
species in the gas phase is ideally suited for heparin, as ESI-generated heparin
polycations are largely alkali metal- and ammonium adducts, rather than
protonated species, which is likely to make the use of proton transfer reactions for
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the charge reduction purposes ineffective. However, electron transfer to a heparin
(or heparin-containing) polycation generates a free radical, which may induce ion
fragmentation in the gas phase. If the charge reduction is not accompanied by
collisional activation of ions, such fragmentation events are unlikely to lead to
dissociation (physical separation) of the fragments in the gas phase when applied to
globular proteins and protein complexes, where multiple hydrogen bonds reinforce
ternary and quaternary structures.38 In fact, ion dissociation was never observed in
our previous work when electron-based (both transfer and capture) limited charge
reduction was applied to proteins, their complexes and aggregates under conditions
that minimize collisional activation.28,29,37 However, GAG chains are linear and
unlikely to collapse to globular structures upon transfer from solution to the gas
phase in the ESI interface. Therefore, generating a free radical in the process of
electron-driven charge reduction may conceivably result in dissociation
(fragmentation followed by physical separation of the fragments), unless the
affected chemical bond is part of the saccharide ring (in which case a cross-ring
cleavage would be required for dissociation).
To evaluate the likelihood of such unintended dissociation of heparin and
heparin-containing polycations in the gas phase when collisional activation is
minimized, we applied the limited charge reduction technique to the ions
representing free (unbound) heparin in the mass spectrum of the AT/heparin
mixture. Figure 2-2 shows the results of limited charge reduction of ions confined
to a narrow ionic population (m/z 3190-3230) that was selected from the region of
the AT/heparin mass spectrum populated by free heparin ions. The vast majority of
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product ions appear in the m/z region above that of the precursor ions; only a small
fraction of ions representing less than 1% of the total ionic signal appear below the
low-mass cutoff for the precursor ion selection window (see the colored region in
the inset in Figure 2-2) and, therefore, are fragment ions. In addition to these lowm/z fragments, some of the product ions populating the region of the spectrum
above the mass selection window can also be fragment ions (with low charge
states). However, analysis of their m/z values suggests that the vast majority of
them are simply products of ionic charge reduction, and if any dissociation does
accompany this process, it results only in a very small mass change.
This analysis was carried out by assigning a random integer charge state Z to
the precursor ion population within the selection window and calculating the
masses of charge-reduced species Z-1, Z-2, etc. The results of these calculations are
shown in Figure 2-2 with colored arrows, each color corresponding to a specific
mass and charge state of the precursor ions (as indicated in Figure 2-2). Changing
the position of the precursor ion selection window will, of course, allow a different
set of free heparin molecules to be detected, and complete “cataloging” of the free
heparin species would require the precursor ion selection window to be moved
across the entire m/z region of interest (a point that will be addressed later). In the
mass spectrum of the products of limited charge reduction shown in Figure 2-2
there are four different groups of heparin polycations with m/z ratios falling within
the precursor ion selection window, ranging from 16 to 26 kDa. The mass spectrum
does not contain any “orphan” ions in the m/z region above that of the precursor ion
selection window that cannot be assigned as products of charge reduction without
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dissociation. Similar conclusions can be drawn from the analysis of charge-reduced
heparin ions whose precursors were selected from different m/z windows
suggesting that no significant dissociation of heparin polycations occurs as a result
of electron-driven limited charge reduction under conditions that minimize
collisional activation. Even lower dissociation yields are expected for heparinprotein assemblies, where strong electrostatic interactions are expected to provide
additional structural reinforcement in the gas phase.

2.3.3 Establishing the identity of AT/heparin complexes using limited charge
reduction
Even though straightforward use of native ESI MS or IM-MS of the
AT/heparin mixture does not allow meaningful information to be extracted from the
unresolved mass spectra, some spectral features could nonetheless be seen in the
high m/z region that hint at the presence of protein/GAG complexes with different
stoichiometries, each giving rise to a continuum ionic signal. For example, ions in
the m/z region 4500-5500 (immediately above that of AT ions) may represent 1:1
AT/heparin complexes, while the ability of a single heparin chain to accommodate
more than one protein may give rise to ions with higher m/z values. In order to
confirm that and identify the regions corresponding to different protein loading,
precursor ions were selected within broad (100 m/z units) windows and subjected
to limited charge reduction. Three representative mass spectra of ions produced by
limited charge reduction of precursor ions representing the three distinct regions in
the native ESI mass spectrum of the AT/heparin mixture are shown in Figure 2-3.
The m/z values of ion peaks from the well-defined charge ladder representing the
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precursor ions at highest m/z (selection window 6850-7050) can be readily used to
obtain the masses of ions populating this region of the mass spectrum (189, 196,
203, 210 kDa, corresponding to AT3·heparin complex). The analysis of the charge
ladder representing the precursor ions at lowest m/z values (4750-4850) is also
relatively straightforward, yielding four ionic species in the 62−77 kDa mass range
(corresponding, as expected, to AT·heparin complex, vide supra; see the panel
labeled “m/z = 4800” in the Supporting Information for more detail). However, the
mass spectrum of the products of charge reduction of precursor ions confined to the
isolation window m/z 5950-6050 (purple trace in Figure 2-3) is very convoluted
and cannot be interpreted unequivocally without making any assumptions.
This overwhelming spectral complexity is likely to be due to the presence of
multiple AT/heparin complexes whose m/z values fall within a relatively wide
precursor ion selection window. In order to circumvent this problem and to simplify
the data analysis process, another mass spectrum was collected after narrowing the
width of the precursor ion selection window ten-fold (m/z 5995-6005). The
resulting mass spectrum (the cyan trace in Figure 2-4) is indeed greatly simplified
compared to the original spectrum and contains contributions from only three
distinct ionic species corresponding to AT2·heparin complexes with different
heparin chain lengths (14.6, 20.6 and 26.6 kDa, respectively), while the majority of
other charge-reduced species that were prominent in the original spectrum (purple
trace in Figure 2-4) are filtered out. For example, a peak at m/z 6435 is clearly
absent from the charge ladder generated upon narrowing the precursor ion
selection window, suggesting that its own precursor lies outside of the narrow
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precursor ion selection window (m/z 5995-6005); a straightforward analysis yields
an ionic mass of 180 kDa, corresponding to a 3:1 AT/heparin complex (see black
arrows in Figure 2-4). A complete set of the limited charge reduction data (obtained
by moving the precursor ion selection window over the entire m/z region of
interest) is presented in the Supplementary Material section.

2.3.4 Combination of limited charge reduction and ion mobility increases
measurement throughput
Although narrowing down the precursor ion selection window as a means of
limiting the number of different ionic species leads to high-quality MS data, where
mass assignment can be readily (and unequivocally) made, it has one significant
drawback. Indeed, it results in a dramatic increase of the overall data acquisition
time, as a significant number of experiments are required to cover the entire m/z
region of interest to reveal all contributors to the unresolved ionic signal in the
native ESI mass spectrum (e.g., it would require 300 measurements to cover the
entire m/z range 4000-7000 in native ESI mass spectrum of the AT/heparin mixture
if the width of the precursor ion selection window were kept at 10 u, as was done to
acquire data shown in Figure 2-4). To avoid this clearly unacceptable data
acquisition time scale, one may use wide precursor ion selection windows for m/z
regions where relatively modest spectral complexity allows such data to be readily
interpreted (e.g., m/z > 6500 in Figure 2-3), and resort to narrow selection
windows only when necessary (vide supra).
Another possibility to increase the throughput without sacrificing the quality
lies with incorporating ion mobility in the experimental work flow. Even when
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relatively narrow precursor ion isolation windows are used, adding ion mobility
dimension provides an additional advantage of higher resolution, which allows
better distinction to be made among the closely spaced charge-reduced species
representing different precursor ions (Figure 2-5A). This advantage, however, is
not critical, as the ion peaks populating the m/z region above 5500 u in Figure 2-5A
can be readily distinguished from another even without taking the mobility data
into consideration, although the 2-D data presentation (using both m/z and the
mobility dimensions) does allow the charge state assignment of the product ions to
be verified by localizing on a single diagonal a group of ions having the same mass
but different number of charges on a single diagonal. More importantly, inclusion of
the ion mobility step in the measurement scheme allows meaningful information to
be extracted even when a wide m/z window is used for selecting the precursor ions
(Figure 2-5B). Even though no distinction can be made in this case among the
charge-reduced species along either m/z or the drift time axes alone, the distinct
ionic signals are clearly discernable in the 2-D diagram, revealing the presence of
1:1 AT/heparin complexes with relatively short heparin chains (ranging from 4.5
kDa to at least 13.5 kDa). At the same time, these “broad-band” experiments provide
substantial improvements vis-a-vis measurements’ throughput, as the data
acquisition time for a single measurement is independent of the window’s width
(both mass spectra shown in Figure 2-5 were acquired within 20 min, but a wider
precursor ions selection window allows fewer experiments to be carried out to
cover the entire m/z region of interest).
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2.3.5 Interpretation of AT/heparin mass spectrum based on the limited charge
reduction data
Application of the limited charge reduction to ions selected from different
regions of the native ESI mass spectrum of AT/heparin mixture allows various
spectral features to be readily assigned as contributions of complexes with different
stoichiometry, as well as free heparin. The mass and charge state ranges obtained
for these species in the course of limited charge reduction measurements allow the
deconvolution of the unresolved mass spectrum of the AT/heparin mixture to be
carried out (Figure 2-6). The most important assumption made here was that the
distribution of charges for ions representing an ATx·heparin complex at each
specific stoichiometry fits normal (Gaussian) distribution, which had been shown
before to work well with homogeneous protein ions generated by native ESI.39-41
However, unlike homogeneous populations of protein ions, the individual charge
states within each ATx·heparin complex are not expected to be resolved, prompting
us to model the entire population of such ions as a Gaussian curve in the inverse
(z/m) space. The initial positioning of each curve was based on the mass spectral
data provided by limited charge reduction measurements, as shown at the top of
Figure 2-6. This was followed by supervised minimization aiming at achieving the
best fit of the sum of all curves with the experimental data, allowing the
contribution of each ATx·heparin complex (as well as unbound heparin) to the total
ion signal in the mass spectrum of the AT/heparin mixture to be determined.
Although it may be tempting to relate the relative abundance of each type of
complex to its fractional concentration in solution, it is likely that at least some
distortion exists due to the differences in ionization efficiencies, which are known to
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be influenced by a variety of factors (the major one being relative hydrophobicity of
the species in solution42,43). Nevertheless, semi-quantitative conclusions can be
made on the influence of various intrinsic and extrinsic characteristics on the
efficiency of formation of protein/GAG complex formation with a specific
stoichiometry by monitoring the intensity change of the corresponding ionic signal
in response to variation of either environmental factors (e.g., solution ionic strength,
temperature and pH) or the binding partners’ characteristics (e.g., protein
modifications or mutations, alteration of GAG length of extent of sulfation, etc.).
Another important information that can be uniquely extracted from the limited
charge reduction measurements presented in this work is the range of GAG chain
lengths that can accommodate a certain number of proteins (such protein loading
information is particularly valuable in the design of protein drug delivery systems
utilizing GAGs as scaffolds). For example, the 1:1 AT/heparin complexes (signal
component colored in red in Figure 2-6) incorporate relatively short heparin chains
(up to 25 kDa), while complexes with higher stoichiometry use notably longer
heparin chains (up to 36 kDa and 49 kDa for 2:1 and 3:1 complexes, respectively).
The implicit assumption made here is that a single AT molecule cannot
accommodate more than a single heparin chain, which allowed us to determine the
stoichiometry of AT/heparin complexes based on their masses. While there is
unequivocal proof that AT has only a single heparin-binding site,44,45 other heparin
clients may exhibit more promiscuous behavior and accommodate a larger number
of GAG chains, making it difficult to deduce the stoichiometry of the protein/heparin
complex from its mass alone. This problem may be circumvented by introducing a
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separation step (either size exclusion or ion exchange LC) in the experimental
routine presented in this report (this work is currently underway in our laboratory).
Finally, the ability to obtain information on charge state distributions of ionic
populations

representing

various

protein/GAG

complexes

allows

the

conformational stability of the polypeptide components of such complexes to be
evaluated. Not surprisingly, the charge state distributions of all AT/heparin
complexes observed in this work are narrow, and the ionic charge density is low,
suggesting that a compact conformation is maintained in solution.21 However, this
may not be universally true, and the shapes of charge state distributions of ions
representing polypeptide/GAG complexes may provide important clues vis-à-vis the
nature of the interaction (e.g., binding to a well-defined “epitope” on the protein
surface vs. polyanion/polycation interaction that maximizes the electrostatic
attraction by keeping both chains unfolded, which is likely to be the case for heparin
interaction with protamines or protamine-inspired polycations). Finally, the ability
to determine the average charge of ions representing a protein/GAG complex raises
a very intriguing question whether this information can be used to estimate physical
dimensions of these complexes in solution, an approach that had been used in the
past to estimate the size of globular proteins and protein complexes,46 and was later
extended to unfolded proteins, including intrinsically disordered species.47

2.4 Conclusions
Mass measurements of large highly heterogeneous macromolecular ions and
their non-covalent complexes traditionally presented a challenge for native ESI MS;
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even though this technique had been successfully used in the recent past to measure
masses of very large protein assemblies, the best results are usually obtained when
working with highly homogeneous targets. In contrast, the progress had been
relatively modest when the analytical targets are (bio)polymers whose synthesis is
controlled enzymatically or semi-synthetically, rather than genetically. In this
regard, heparin and heparin-like GAGs constitute a particularly “difficult” class of
compounds that exhibit truly intimidating degree of heterogeneity: it challenges the
very notion of molecular mass, which loses its clear and intuitive meaning when
applied to highly heterogeneous species, such as heparin. As a result, analytical
characterization of heparin and heparin-like GAGs (as well as their complexes with
client proteins) were traditionally focused on extracting characteristics averaged
across the entire ensemble; an alternative approach focuses on short homogeneous
mimetics as heparin surrogates, which willingly sacrifices the unparalleled diversity
of intact native heparin. In contrast, a combination of native ESI MS and limited
charge reduction in the gas phase allows meaningful information to be obtained on
individual protein/GAG complexes, including protein loading and the range of the
GAG chain lengths. While the exhaustive characterization of all ionic species
contributing to the continuum signal in native ESI could be time consuming,
introduction of ion mobility measurements into the experimental scheme allows the
measurements be carried out in a broad-band mode, leading to a significant increase
in throughput (as had been observed in other instances when utilization of wide
precursor ion selection windows increased the measurement throughput48). The
analytical capabilities of this method of monitoring GAG/protein interactions will be

36

expanded further by incorporation of an on-line separation step prior to ESI MS
analysis: recently we demonstrated that limited charge reduction can be used in the
on-line format with ion exchange and size exclusion chromatography (manuscript in
preparation). Utilization of an extra separation step that does not compromise the
integrity of non-covalent associations will allow complex GAG/protein systems
(where two or more different proteins are tethered to a single chain) to be
interrogated in a meaningful fashion. This will undoubtedly open up a host of
exciting and previously unavailable opportunities to study interactions between
heparin-like GAGs and a variety of their client proteins, a boon to both fundamental
studies of GAGs, and the design of drug delivery systems relying on GAGs as
versatile scaffolds.
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Figure 2-1. ESI mass spectra of 4 µM AT solutions in 30 mM ammonium acetate
(pH 6.0) acquired in the absence (grey trace) and the presence of 0.03 mg/mL
intact heparin (black trace). Charge states are labeled for ions representing
the β-glycoform of AT (ionic species of the α-form are labeled with circles).
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Figure 2-2. Ions generated by limited charge reduction of a population of free
heparin ions whose m/z values are confined to the m/z region 3190-3220.
Colored arrows indicate positions of charge reduced species corresponding to
precursor ions with different masses and charge states whose m/z values fall
within the selection window. Asterisk indicates an ionic peak that could not be
assigned as a product of charge reduction alone (and, therefore, must
represent fragment ions).
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Figure 2-3. Native ESI mass spectrum of the AT/heparin mixture (black trace)
and three representative mass spectra of ions produced via limited charge
reduction of precursor ions whose m/z values fall within 4450-4550 (red),
5950-6050 (purple) and 6850-7050 (blue) m/z regions.
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Figure 2-4. Limited charge reduction mass spectra obtained using wide
(purple) and narrow (cyan) precursor ion selection window. The ionic species
labeled with A, B and C represent resolved charge-reduced species whose
precursor ions’ m/z values fall within both the broad and the narrow selection
windows (calculated masses are 138.1, 132.1 and 126.1 kDa, respectively).
The black arrows indicate positions of several charge-reduced species and
their common precursor ion that had been filtered out by switching for the
broad to the narrow selection window.
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Figure 2-5. Mass spectra (cyan traces) and ion mobility mass spectra (2-D
diagrams) of ions produced by limited charge reduction of precursor ions at
m/z 4500 isolated using a narrow selection window (window width 10 u,
panel A) and a wide selection window (window width 100 u, panel B). The
resolved charge-reduced species are circled and their masses/charge states
labeled.
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Figure 2-6. Extraction of contributions of ATx·heparin complexes to the total
ionic signal in the native ESI mass spectrum of AT/heparin mixture based on
the results of limited charge reduction measurements. The number of AT
molecules in each ionic species is indicated on each curve; the black line is the
summation of all individual contributions (best fit to the experimental data
shown in gray). The colored bars at the top of the graph show m/z ranges for
each species provided by limited charge reduction measurements.
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CHAPTER 3
ION-MOBILITY MASS SPECTROMETRY COUPLING WITH LIMITED CHARGE
REDUCTION REVEALS DISTINCT MODELS OF INTERACTION BETWEEN
HEPARIN AND PROTAMINE SULFATE†

3.1 Introduction
Heparin as one of the best known glycosaminoglycans (GAG) is the most
negatively charged natural polymer to our knowledge with mass ranging from 3kDa
to 23kDa (Figure 3-1A)1. It can interact with a broad range of proteins including
many coagulant factors2 and other clinically relevant binding partners. Heparin
(usually in the form of a heparinase digestion mixture with low molecular weight)
are widely used in medicine as an anticoagulant.3 Protamine is a family of small
arginine-rich proteins (50-100 amino acids) synthesized in eukaryotic sperm cells
for packaging chromosomal DNA4 The highly dense positive charge also allows
protamine to potentially interplay with heparin, thus one derived drug, protamine
sulfate, also simplified as protamine in this paper, has been widely used as a natural
antidote of heparin, for instance, during the closing of a surgery in order to restore
the level of platelet aggregation that has been originally suppressed by low
molecular weight heparin5,6. The interaction between heparin and protamine has
also been utilized for making heparin sensors7, protein therapeutic delivery systems
and tissue engineer scafolds8,9. The sequence of protamine is genetically encoded,
varying in different species (Figure 3-1B). It may result in alternative secondary
This entire chapter with be submitted as a manuscript for publication after further
edition.
†
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structures and affinity with heparin. A complete analysis of above information has a
practical value in the sense that quality control and comparability study can be
achieved for the protamine produced from different sources and batches. Some
techniques for particle size analysis (e.g. dynamic light scattering and analytical
ultracentrifugation) have been proved to be a valuable tool to probe the behavior of
protamine and heparin interaction10. However, these methods were limited to
estimate the size of particles in nanoscale (with diameter 30~60nm) and it lacks
accuracy for approaching stoichiometry when the complex is initiated in the early
stage. And routine structural characterization tools (e.g. X-ray crystallography and
nuclear magnetic resonance), although can create models for protamine itself and
protamine/DNA complex11,12, is very challenge to solve a meaningful model of
protamine/heparin complex. One reason is that these tools have low tolerance of
heterogeneity13 in a sample like protamine/heparin mixture, where extensively
variable sulfation patterns of heparin and diverse sequence of protamine may give
rise to many species with different stoichiometry and structure.
Traveling wave ion-mobility mass spectrometry (TWIM-MS) has been widely
used in mass analysis and structural characterization of macromolecules.
Measurement of arrival time provides information correlated to the physical size of
the ionized molecules. Intriguingly, it can be directly performed to resolve the
components in a sample containing multiple species, such as a polymer with broad
mass distribution, or a mixture of protein oligomers differing at the number of
subunits and topology14,15. However, TWIM-MS-based approach has been limited to
the well-resolved species whose mass and charge state can be determined
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accurately for the purpose of collision cross section (CCS) calculation. And therefore
a direct CCS determination is impossible when analytes are poorly resolved under
native condition such as glycosylated proteins and most likely in the case of
protamine and heparin complexes.
Previously, we reported that electron transfer-induced limited charge
reduction (LCR) of a selected ionic population was an unparalleled solution in order
to decrease the bias of charge state assignment caused by peak convolution in a
mass spectrum acquired from heterogeneous samples such as glycoprotein16,
protein complex17 and aggregation18. We recently reported another case with this
technique to characterize stoichiometry of the complexes formed by antithrombin
and unfractionated heparin under the native condition. Without doing limited
charge reduction, the mass spectrum was fully unresolved and only displayed
several bad-shaped ionic clusters with nearly a continuous m/z, because of
insufficient desolvation and extensive degree of ammonium ion adduct19.
Nevertheless, limited charge reduction allowed us to resolve all species existing in
the same isolation window and reconstruct the distribution of the complexes
through placing isolation window across the entire m/z range. In the same work, we
also demonstrated that use of a post-LCR ion-mobility separation dramatically
enhanced the resolution of charge-reduced species. The different charge-reduced
populations were readily separated in the drift time domain even though the mass
spectrum itself is very convoluted when the isolation window is broad.
In the current paper we investigated a mixture of protamines and heparin
oligosaccharides under the native condition using TWIM coupling with limited
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charge reduction. Our data provides novel insights of stoichiometry and
conformation for the protamine/oligosaccharide complexes during the early stage
of the particle formation.

3.2 Experimental
3.2.1 Materials
Protamine sulfate was provided by United States Pharmacopeia. Heparin
oligosaccharide isolated through size exclusion chromatography was purchased
from Iduron (UK). We used the fraction predominantly consisting of the
oligosaccharide with twenty saccharide units, thus referred as dp20. Protamine and
dp20 powder were dissolved into distilled water (Millipore, MA) initially to make
stock solutions then diluted as 10mg/ml with 150mM ammonium acetate at pH=6.9.
We mixed protamine and dp20 at 1:1 ratio (g/g) and directly used them for
chromatography analysis or native mass spectrometry without extra time for
incubation.

3.2.2 Online Ion-exchange Chromatography-Native Mass Spectrometry
Ion-exchange chromatography was carried on using Agilent 1200 HPLC
system equipped with a weak cation exchange column ProPac-100 (Thermo
Fischer). The column was equilibrated with 10mM ammonium bicarbonate at
pH=8.5 prior to sample injection. Gradient elution was applied by increasing the
concentration of ammonium bicarbonate up to 500mM at the same pH. No extra salt
was added into the mobile phase. A 7T Bruker SolariX FT-ICR mass spectrometer
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was used for online mass spectrometry analysis. To get better ionization
performance, the inlet flow for electrospray source is reduced to 20µl/min via a
splitter after the fluid pass through the column. Data acquisition was triggered with
Hystar software.

3.2.3 Ion-Mobility-Mass Spectrometry Coupling with Limited Charge
Reduction
The protamine dp20 mixture was introduced to the gas phase using Synapt
G2S equipped with nanospray source. In order to create a gentle source condition
with well ionization efficiency, capillary voltage was 1.5 kV, source temperature
remained at 80 °C, cone voltage was 10 V. Limited charge reduction was carried on
basically following a modified procedure for regular electron transfer dissociation.
Briefly, a narrow ionic population within specific m/z window was isolated using
quadrupole first, LM resolution was set to 3.9 and HM resolution was set to 12. Then
electron transfer reagent 1,3-dicyanobenzene was introduced into the trap to
interact with analyte ions and induce their limited charge reduction. The vacuum
and traveling wave height in the trap cell were optimized so that a remarkable
charge reduced populations can be observed. For ion-mobility separation of charge
reduced ions, IMS wave velocity and height were set to 300 m/s and 25 V,
respectively; vacuum reached 3.5 mbar in helium cell and 2.5 mbar in IMS cell. Trap
DC bias was ramped to 35 V in order to achieve sufficient ion transmission.
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3.2.4 CCS Calibration
A couple of standard proteins with small CCS and mass value including native
cytochrome C, BLG and denatured ubiquitin was run at the same condition as for the
protamine dp20 mixture. Calibration curve was created based on IM-MS following
the regular protocol described in reference (15).

3.2.5 Data Analysis
Online IXC-MS data were processed using DataAnalysis software (Bruker
Daltonics) and LCR-IM-MS data were analyzed using Masslynx and Driftscope
software (Waters). CCS plot fitting was done using Origin Pro (Northampton, MA).

3.3 Results and Discussion
3.3.1 Electrostatic Interaction Between Heparin and Protamine Can be Probed
using WCX-MS
Online WCX-MS enables a real-time monitoring of eluents as ionic strength
increases, although the use of ammonium bicarbonate may not have the same
performance of separation as sodium chloride does. We observed that dp20 eluted
immediately before the gradient elution step started, indicating that dp20 was
negatively charged at pH 8.5 and was not retained on the column (Figure 3-2, the
top panel). In contrast, protamine itself only eluted at high ionic strength. Extracted
ion chromatogram rendered two fractions in the protamine sample based on their
retention times (Figure 3-2, the bottom panel, left column). The late eluted fraction
represented the protamine species with higher mass and more positively charged
residues. However, the retention of protamine on the column was fully eliminated in
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the presence of dp20 (Figure 3-2, the middle panel). We found protamine species
with higher mass were eluted together with dp20. The result clearly suggested that
a charge neutralization and an interaction occurred between polyanions and
polycations, although we did not observe ionic signals corresponding to the mass of
protamine dp20 complexes (>9000Da) under the applied harsh desolvating
conditions chosen for the online experiment. Interestingly, the signals of several
protamine species with lower masses (like the one shown in the yellow trace in the
bottom panel of Figure 3-2) were invisible. That is perhaps because the ionic
signals of less abundant species were suppressed during ionization if they are not
separated by ion-exchange chromatography.

3.3.2 Characterization of Complexes Formed by Protamine and dp20 using
Native Mass spectrometry with Limited Charge Reduction
To examine whether the observed charge neutralization can be attributed to
a direct interaction between protamine and dp20, we analyzed the mixture under
native conditions using mass spectrometry. The mass spectrum of the mixture
displayed extensive ionic signals but only a small portion of them were partially
resolved (below 1500 m/z) and they corresponded to the unbound dp20. All ionic
signals from m/z=1500 to m/z=3000 were completely unresolved and suggested an
ionic cluster with signals at every single m/z value (as shown in the top panel of
Figure 3-3). To measure the mass of the cluster, we isolated precursor ions at
m/z=2300 and induced limited charge reduction. A series of well-resolved product
ions appeared in the m/z region from 2500 to 5000. Interpretation of those chargereduced ions was done by following the same approach described in previous
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work.19 The intensity of charge-reduced ions was sufficient for us to assign charge
states based on the spacing between two correlated peaks and to calculate their
mass then. As a result, three ionic species with different mass were characterized in
the isolated ionic population (as indicated in the middle panel of Figure 3-3). It was
straightforward to determine the 6,900Da and 9,200Da species to be two complexes
of protamine and dp20 at 1:1 ratio based on the individual mass range for dp20
(3,360-5,760Da) and for protamine (3,000-4,500Da), respectively. The third mass at
11,500Da must be a ternary complex however we cannot assure the ratio of
protamine and dp20. Obviously, either the complex with a single protamine chain
and two dp20 chains or the one with a dp20 chain and two protamine chains can
both show masses of 11,500Da. This is a common issue that we cannot just base on
the mass value itself to assign a complex stoichiometry when the theoretical mass
ranges of two heterogeneous binders are largely overlapping.

3.3.3 Ion-Mobility Separation and CCS measurement of Charge-Reduced
Product Ions
First, we investigated a precursor ion with relative low m/z (1600) using
limited charge reduction. As shown in Figure 3-4, we observed five distinct ionic
populations in the ion mobility mass spectrum. The ionic signals within the m/z
region from 1490 to 1650, originated from the isolated precursor, were divided into
two populations in the drift time domain, centering at 4.3ms and 5.18ms
respectively. They were subjected to limited charge reduction and then generated
other three populations, being further separated according their drift times and m/z
values. By a manually deconvoluting those peaks, we can promptly find two sets of
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charge ladders corresponding to the ions with molecular weight 4800Da and
6400Da respectively (labeled in different colors and summarized in Figure 3-4).
Clearly, the involvement of ion-mobility increased the resolving power for the
different ionic species by providing an extra dimension of separation. It was also
noted that the peaks of both precursor ions and charge reduced product ions in ionmobility mode remained broaden and displayed more signals below the desired m/z
values (set in the quadrupole) compared to those in the spectrum acquired when
ion-mobility separation was off. These tailing signals were probably induced by the
shedding of sulfate group under an enhanced DC bias voltage applied in the trap cell,
which was required for a sufficient ion transmission through the ion-mobility cell
against the buffering nitrogen gas.
Next we calculated the collision cross sections for each observed ionic
population (listed in the table under Figure 3-4). To be noted, a precursor ion and
its multiple charge-reduced states had very intimate CCS values (standard deviation
< 0.2) suggesting that the physical size of a polymer ion remained the same during
the charge-stripped process in the gas phase. Therefore, the similarity of CCS
between different charge states can be a criterion for checking whether correct ionic
species were picked up as one charge ladder representing the same precursor ion.

3.3.4 Data from Specific m/z Regions Revealed Distinct Species with the Same
Mass
To identify the complexes in the mixture, the precursor ions at other m/z
value across the entire region where ionic signals displayed were isolated and
subjected to limited charge reduction. We compared the IM-MS at precursor at
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m/z=2400 with the mass spectrum without ion mobility at the m/z=2300 (the
bottom two panels of Figure 3-3). This small discrepancy on precursor m/z value
selection (i.e. 2300 vs. 2400) was kept only to provide better alignment of peaks due
to the consideration of the tailing in the spectrum acquired in the ion-mobility
mode. From the ion-mobility mass spectrum, some additional information can be
extracted. First, a new charge ladder representing a 13,800Da precursor ion with +6
charge state was exclusively identified in the ion-mobility mode. We can clearly
noticed that its reduced charge states (+4ß6) (representing the +4 product ion
reduced from the +6 precursor ion) was thoroughly overlapped in the m/z domain
with the product ions reduced from another precursor charge state (+2ß3) of
6,900Da, however these two species can be separated in the drift time domain due
to the remarkable differences in charge. Similarly, IM-MS enabled the distinction
between two ionic populations, (+3ß6) of 13,800Da and (+2ß4) of 9,200Da.
Although significantly driven by charge difference between individual
populations, the IM-based separation can also distinguish two populations with
differences in physical size (CCS values) when they had the same mass and charge.
Indeed, for the 11,500Da species, two populations of charge series presented with
different drift time values, corresponding to two species with the same mass but
different CCS values. We also observed two populations of distinct CCS for multiple
charge states of 13,800Da ions. We hypothesized that the second population was
not converted from the other in the gas phase. To verify this hypothesis, we
investigated the same charge state +3ß4 generated from four different precursors.
As illustrated in Figure 3-5A, it was that the population with larger CCS (referred to
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as population B) did not appear until the mass reached a value between 8,800Da
and 9,600Da and then the relative abundance of B continued to grow as the mass
increases. This observation strongly suggested that the population B, representing a
conformation or stoichiometry differing from A, can only formed over a specific
mass range, reflecting the presence of the species in the solution. We also observed
that the population A had more tailing signals than the population B, suggesting that
the population A was composed of higher degree of heparinoid component, which
offers more opportunity of mass decrease related to sulfate group shedding. For
example, the population A could represent the complex with one protamine and two
chains of dp20, and the population B could represent the complex with two
protamine and one dp20 because the theoretical minimal mass of the latter
stoichiometry is about 9360Da (3000+3000+3360) and just falls in the proposed
mass range determined upon above. In a conclusion, ion-mobility-enabled analysis
on limited charge reduction data provides additional hints on the potential
stoichiometry and conformation of the complex.

3.3.5 Comprehensive Analysis of Stoichiometry and Conformation based on
CCS-Mass Relationship
This approach only focused on the well-resolved charge-reduced populations
to extract the CCS, mass and charge information of species that coexist within the
precursor isolation windows and overlooked the ions without good separation,
including the precursor ions themselves. For the precursors at m/z=2400 (Figure
3-3, the bottom panel) as an example, the ionic signals falls within 2200-2400 are
very convoluted thus we were unable to precisely extract the drift time value for
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each populations. One remaining questions is whether the CCS is unique for a
specific ion and not related to the charge state of precursor. To elucidate this point,
we compared the CCS of the same ion generated from three different charge
reduction processes in the gas phases, presented in Figure 3-5B. For a specific
molecule of 12,000Da, the +3 charge ion (m/z=4000) can be reduced from three
precursor ions with different charge states +6, +5, +4 (see the ionic populations of at
m/z=2000, 2400, 3000 respectively) and all of these +3 products produced
consistent CCS values (about 11.16nm2) no matter what precursor it was born
from), indicating that they represented the same specie in terms of mass and
stoichiometry. The consistency of CCS also happened on +4 charge ions except for
the +4 precursor itself, of which the CCS is not available due to the convoluted
signals fallen within the selection window. These observations strongly suggests an
universal conclusion that if a molecule is ionized to different positive charge states,
the CCS of the ion at charge state n is identical to the CCS of the ion at (n+i) charge
state when it is reduced to charge state n in the gas phase. In another word, the CCS
of one charge state is relatively independent to the pathway in which the ion is
generated. Besides in the case of complexes formed by protein and linear polymer,
this conclusion has also been validated for other types of macromolecule such as
native single proteins including albumin and β-lactoglobulin (data not shown) and
denatured ubiquitin20.
Because the mass and CCS of a complex were independent to the displayed
charge states, we can plot the CCS values of all available ions versus their masses to
elucidate the relation between stoichiometry distribution and the mass of the
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complex, as shown in Figure 3-6, where the two ions with the same mass but
significant difference on CCS values (such as population A and B in Figure 3-5A) are
in different colors. All of those data points were fitted by three individual trends, in
which the CCS value increases monotonically as mass increases. The first curve on
the bottom covers a relatively low and narrow mass range (5,000Da-7,000Da). It
may represent unbound dp20 and dp20 non-specifically binding with contaminant
molecules (such as PEG). Because dp20 is a chain with fixed number of saccharides,
the CCS increase can only be attributed to number of sulfate group (or ammonium
adduct) increasing. The enhanced repulsion between negatively charged sulfate
groups makes the chain less compact. The other two curves represent protamine
and dp20 complexes. Interestingly, based on the wide mass range of the middle
curve (6,000 – 24,000 Da), it may be a combination of multiple stoichiometries. The
same types interpretation of IM-MS data can be seen in previous IM-MS study on the
mechanically interlocked polymers mixture, where the complexes contain a polymer
chain with variable mass and a number of macrocycles.21 Therefore, based on the
experimental mass range, we hypothesize that the middle trend is the protamine
heparin 1:1, 1:2 and 1:3 complexes and the top trend is the protamine heparin 2:1
and 3:1 complexes. The rationale of this assignment can be verified through their
potential structure features, which is discussed as follow.
There are several studies that suggested that certain types of protamine has
an irregular helical structure with all charged arginine side chains toward outside22.
An X-ray crystallography12 and NMR11 study also revealed that the side chains on
the protamine helix can interact with the grooves of double strand nucleic acids.
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Another recent molecular dynamic study illustrated the interface between
protamine and heparin23. All these data imply that a protamine molecule is very
compact compared to a dp20 molecule with the same mass. Therefore two different
models regarding how protamine and dp20 can form complexes are proposed upon
the two trends (in orange and cyan in Figure 3-6) respectively. One model contains
one or two protamine as the building center and all dp20 chains wrapping around
the protamine core. The second model contains multiple protamine molecules
bridged by one or two heparin chains. Obviously the model II has a more extended
conformation (as shown in the cartoon of Figure 3-6). Both model I and model II
may represent the early stage of the growth of protamine/heparin-involved
particles at various ratios of mixture. And they can only coexist when the
concentration of protamine and dp20 is low. If we keep increasing the concentration
of either on or both, it will induce the formation of larger complex, giving rise to an
insoluble aggregation eventually. In model I, the complex can grow large under the
shielding from excess amount of dp20. Model II is favored when protamine is in
excess. However the extended structure of model II is quite unstable and it does not
allow the complex to expand too much, otherwise, the hydrophobic surface of
protamine may easily facilitate precipitation immediately24.

3.4 Conclusions
Native ESI-IM-MS provides an elegant means to probe the topology of small
protein units aggregates, such as the discovery of the various models of β-amyloid
related complex formation,25 however it is not straightforward to apply this
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approach to analysis of a heterogeneous systems. We divided the task of dissecting
entire ionic cluster into multiple small portions, only focusing on the ions falling
within a narrow isolation window. Through identifying and recording mass, charge
and CCS (and the relative abundance for a validation purpose) for all populations in
the small portion of cluster using limited charge reduction, we can finally
reconstruct a complete picture depicting the distribution of each type of complexes
from the giant unresolved cluster. This limited charge reduction is the only
“magnifying scope” that allows us to look at a fully unresolved spectrum in a
meaningful way.
Electron transfer induced charge reduction occurs very efficiently in proteins
and other ions with higher positive charges without creating significant
fragmentation. Unlike proteins, heparin-involved protamine cannot attract ample
electrons due to Coloumb’s force and it would be difficult to generate adequate
charge-reduced states that will be utilized for accurate mass and charge assignment.
And the measurement of the CCS for charge-reduced populations may fill this gap by
providing an extra criterion to examine the initial charge state assignment. Another
unique property of protamine dp20 complex is that its lower charge state has an
enlarged CCS in most cases, differing from what we previously learned from studies
on proteins, which follows an opposite law that the CCS gets smaller when charge is
reduced20,26. One possible reason is that the electrons initially transferred to the
complex will release part of the GAG chain wrapped on the protamine and the
increased repulsion between highly dense negative charges of GAG makes the chain
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more extended, if we assume the conformation of GAG chain makes the major
contribution to the CCS of the entire complex.
Although we tried to correlate the CCS values to some structure models, we
are aware of that we would never build a robust structure model without other in
silico modeling approaches such as molecular dynamics simulation as well. We can
regardless treat the CCS-mass profile as a fingerprint, which records unique
information in terms of the distribution of different types of complexes in the
solution. By monitoring the CCS-mass fingerprint in response to the change of
experimental parameters (e.g., the ratio of mixture and the length of saccharide) and
the conditions of the solution (e.g., ionic strength and pH), we can evaluate the
interactions between protamine and heparin, which is critical to both basic studies
on mechanism of protamine/heparin aggregation and the practical applications
such as design of protamine-heparin based delivery system and method
development for quality control or comparability study in the filed of pharmaceutics.
In addition, the approach we described in this chapter can be applied to other
heterogeneous system for structural characterization.
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Figure 3-1. General structure of heparin and protamine. (A) Template of low
molecular weight heparin. The red color indicates where the modifications
(acetylation and sulfation) perhaps occur. (B) The primary structure of
protamine sulfate. It is a mixture of subtypes P1 to P4, encoded in different
genes.
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Figure 3-2. Online WCX-MS of dp20 alone (top), dp20 in the presence of
protamine (middle) and protamine alone (bottom). UV traces and base peak
chromatogram are shown in the left column. The mass spectra of analytes
were shown in the right column are the average of scans within time windows
indicated by the arrows in the left column. The asterisk sign indicates
contaminant (PEG) peaks.
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Figure 3-3. Top: mass spectrum without incorporating ion isolation; Middle:
mass spectrum for limited charge reduction with precursor ion selection at
m/z=2300; Bottom: ion mobility mass spectrum for the limited charge
reduction with precursor ions selection at m/z=2400. The number in the
basket indicates how many species were observed.
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Figure 3-4. Analysis of charge reduced species for the precursor selected at
m/z=1600.
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Figure 3-5. (A) Ion mobility spectra (drift time v.s. intensity) for the ion with
+3 charge reduced from +4 charge precursor isolation. All peaks are fitted
into Gaussian curves. (B) Comparison of CCSs of the same ion reduced from
different charge states.
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Figure 3-6. CCS v.s. mass plot for all detectable ions (including precursor and
charge reduced ions). All points are fitted in three individual curves with
given equations. Proposed stoichiometry and conformation of the protamine
dp20 complex are illustrated in cartoon. Red color indicates the +4 ion
precursor that is not distinguished from other ions at m/z=3000.
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CHAPTER 4
MAPPING MINIMAL PROTEIN-BINDING MOTIFS USING AN ION-MOBILITY TOPDOWN MASS SPECTROMETRY APPROACH‡

4.1 Introduction
Heparin is a highly sulfated glycosaminoglycan (GAG) and is the most densely
negative charged natural-occurring polymer. It is known for its roles in regulation of
coagulant cascades. Heparin is a broad-spectrum anticoagulant reagent that has
been used in many circumstances ranging from treatment of thrombosis diseases to
avoidance of blood clots during surgical operation and intravenous therapy1-3. In
addition, heparin-like GAG can bind to a large numbers of proteins through a
general polyanion-polycation interaction, exemplified by γ-interferon4 and the
family of growth factors (GF). It is well-established that growth factors can trigger
numerous signals correlated to cell proliferation and differentiation when binding
to growth factor receptors (GFR)5 and the GF-GFR dependent signaling can be
facilitated by the involvement of heparan sulfates, a heparin-like GAG that anchors
on the surface of cellular matrix. Although the majority of heparin-related
application still revolve around its anticoagulant effects, the use of heparin to build
nanomaterials (see section 1.1.1.2) has become into an emerging technique in
medical fields such as tissue engineer and therapeutic protein delivery6.
A prerequisite to understanding the mechanism of heparin/protein
interaction is to learn the structural detail in the “binding motif” where specific
This entire chapter with be submitted as a manuscript for publication after further
edition.
‡
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modification patterns (including O-sulfation, N-sulfation and N-acetylation) within a
limited number of saccharide units are required for interaction with client proteins.
The bottom-up approach to identification of the binding motif has been successfully
explored in past decades: a library of oligosaccharide with combinatory segments
was applied on a client protein-conjugated mobile phase for separation based on the
affinity. The pool containing the strongest affinity species was analyzed by mass
spectrometry and tandem mass spectrometry.7 However, comprehensive analysis of
binding motif is extremely time-consuming as the heterogeneity in the samples
caused by the variety of chain lengths and modifications increases. For these
reasons, our knowledge of binding motif of heparin is only available in a few of cases.
Herein we describe an alternative top-down approach that can be applied on
the complex formed by protein and unfractionated glycosaminoglycan and enable a
rapid estimation on number of saccharide and sulfate groups within the required
minimal length of saccharide units without requiring complicated sample
preparation steps. Although the intact heparin is heterogeneous, the saccharide
units and sulfate groups that actually contribute to the binding are always limited to
a small number of combinations. In addition, electrostatic interactions are
strengthened when samples are introduced into the gas-phase, where the shielding
effect of solvent molecules has been minimized. We hypothesize that heparin chain
segments that are not bonded to the protein surface will fragment very readily upon
collisional activation (via both glycosidic bond cleavage and sulfate “shedding”),
while the units involved in interaction with the protein will remain bound to it
(although they may lose “external” sulfate groups not stabilized by salt bridges with
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the protein basic groups) (Figure 4-1). However, as a potential pitfall, unexpected
protein unfolding during collisional activation may damage the protein
conformation residing in the binding region and lead to a GAG releasing from
protein surface before being cleaved. To the date, the relation between unfolding
and dissociation of protein-polyanion complex in response to collisional activation
has not been explored. In this work, we will investigate the feasibility of this
approach on a well-studied system: acidic fibroblast growth factor (FGF) and
oligosaccharide heparin with fixed number of saccharide units. We are also
reporting the relevant behaviors of gaseous ion of protein-heparin complex under
collision activation.

4.2 Experimental
4.2.1 Materials and Sample Preparation
Recombinant human FGF-1 protein (FGF) was purchased from GenScript.
Synthetic heparin mimetic pentasaccharide ArixtraTM (dp5) was a gift from Prof.
Robert Linhardt at Rensselaer Polytechnic Institute. Heterogeneous heparin
enzymatic degraded products with five disaccharide units (dp10) was purchased
from Iduron (UK). Prior to mass spectrometry analysis, FGF was incubated with dp5
or dp10 in buffer containing 100mM ammonium acetate at pH 7. All proteins for CCS
calibration were purchased from Aldrich Sigma (St. Louis, MO).
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4.2.2 Methods
The mixture of FGF and dp5 or dp10 was directly analyzed using Waters
Synapt G2Si mass spectrometer equipped with nanospray ion source (Milford, MA).
Capillary voltage was set to 1.2V. Sampling cone voltage was 20V. Source
temperature was set to 30 °C. In the ion-mobility mode, traveling-wave of the IMS
cell was tuned up in order to get good drift time peak shape and position. Trap DC
voltage was kept at 35V.
Gas-phase mass shedding and protein unfolding were monitored through
MS/MS experiment induced by collision with the argon gas. Ionic population
representing FGF alone or FGF-GAG complex was isolated using quadrupole.
Collision voltage was applied prior to ion-mobility separation and it was gained
stepwise with 10V interval until it reached 120V. This voltage frame was chosen
based on the property of ion and instrumentation condition. If applied collision
voltage goes beyond certain experimental frame, the ions with overwhelming
kinetic energy will be immediately scattered and unable to arrive to the TOF
analyzer to generate any meaningful MS/MS data. Ion-mobility mass spectra under
different energy were acquired for 2 to 5 minute for each to make sure sufficient
signal-to-noise ratio can be achieved for analysis. Acquired data were interpreted in
two different ways: i) collision-induced unfolding (CIU) fingerprint graph was used
to describe the unfolding profile8 of the protein in the gas phase against different
activation energy in the presence or absence of GAG ligands; 2) collision-induced
dissociation (CID) was used for monitoring the mass loss of the protein-GAG
complex responding to the bond cleavage (including S-O and glycosidic bonds in

73

GAG and peptide bonds in protein). CIU/CID followed my IMS/MS measurement has
been applied for characterization of a protein binding to ligands of structural variety
such as lipid9.
Collision cross section (CCS) of an ion was acquired based on the drift time
value at the apex of a peak in the ion-mobility spectrum. To convert drift time to CCS
value, we took advantage of a calibration curve generated by acquiring the ion
mobility mass spectra of a series of native protein with established CCS values
including Cytochrome C, β-Lactoglobulin, Bovine serum albumin and Alcohol
dehydrogenase under equal instrument condition. Charge state and mass of ions
were considered to eliminate the effect of electric field on drift times before plotting
them against the CCS values. The detailed steps for CCS calibration was described in
the standard protocol for protein complex CCS calibration10.

4.3 Results and Discussion
4.3.1 General Behaviors of Unbound FGF in response to the Gas-phase
Collisional Activation
The observed spectrum of FGF alone displayed three charge states
corresponding to a mass at 15,900 Da (Figure 4-2A, the top panel). The CCS value
upon the major charge state (+8) is 18.34nm2, close to the number extracted from
the crystal structure11, revealing that the protein has a similar conformation
presented in the native state. We investigated the unfolding profile of FGF protein
by stepwise increasing the collision voltage in the trap, where selected FGF ions can
be activated and all metastable populations can be captured by IM-MS. As the
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collision energy was increased, two other major populations of FGF at +8 charge
state were generated, displaying enlarged CCS values compared to the native state.
These two populations represent two intermediate conformations during the gasphase unfolding. The first intermediate has modest size expansion (14% CCS
enhancement) and it implies that the protein backbone is rearranged to an
extensive conformation in certain region(s); thus it is referred as a “partially
activated” state. The second intermediate has 30% expansion compared to the
native CCS and it may represents a state where the protein globally loses its
structure features, thus referred as a “fully unfolded” state. The transition between
different states can be monitored using the CIU fingerprint (Figure 4-3A). For
instance, the +8 charge state of FGF can present its partially activated state at an
applied energy as low as 32eV. In this chapter, the applied energy is defined to be
the product of applied trap collision voltage and the charge state of the selected ion.
And the fully unfolded state appeared when the applied energy was above 100eV. It
became an exclusive population when the applied energy reached 220eV and the
populations of first two states were completely converted to the fully unfolded state.
The measured CCS values of a FGF in other charge states are reasonable as
well. FGF+7 had smaller CCS value (17.5nm2) than FGF+8 because of the reduced
Coulomb repulsion amongst positive charges. Relevant molecular dynamic
simulation studies have suggested that during collision-induced unfolding the
conformational change of a gaseous protein ion is associated with the migration of
charged atoms such as protons and salt adducts12,13. As a reasonable hypothesis, the
conformation of different intermediate states and the energy threshold to induce
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the transition between different states are likely to be affected by the actual surface
charge. Indeed, given our results shown in the CIU fingerprint (Figure 4-3, A vs. B),
both of the two intermediate states of FGF still existed in the lower charge state
FGF+7; and they had relatively smaller CCS values compared to the higher charge
state FGF+8. We also observed that FGF+7 was more resistant to collision-induced
activation than FGF+8. For FGF+7, the energies triggering the first transition (from
native state to the partially activated state) and the second (from the partially
activated state to the fully unfolded state) were definitely improved compared to
those for FGF+8, because we can clearly see that the partially activated state of FGF+7
did not appear until 200eV (vs. 32eV for FGF+8) and it remained as the dominant
population across the entire energy range in our experimental frame (up to 770eV).
In addition, the population of the fully unfolded state remained in modest
abundance (<10% of the total ionic intensity). We anticipated that the energy that
was capable to induce majority of fully unfolded FGF+7 is out of the experimental
frame.
Collisional activation also caused ubiquitous protein fragmentation for both
+7 and +8 charge states in company with protein unfolding. It should be noted that
even in the case of +8 ion, where protein unfolding is easier and protein
fragmentation is more dramatic, a population of parent ions survives and can be
distinguished from the ionic signals of fragmentation in the ion-mobility mass
spectra, as shown in Figure 4-S2A.
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4.3.2 Collision-induced Unfolding and Dissociation of the Complex Formed by
FGF and Homogeneous Pentasaccharide
The rationale of the top-down approach for identifying FGF-binding heparin
segments was initially tested using a synthetic pentasaccharide (dp5), which
contains a homogeneous structure and modification pattern. Although this molecule
was originally designed as a mimetic of a heparin segment for antithrombin
modulation, it can bind to FGF as well because it consists in critical structural
features related to the FGF-binding affinity14 (highlighted in Figure 4-2B). The
interaction between dp5 and FGF can be directly probed using native mass
spectrometry (Figure 4-2A). The spectrum of FGF in the presence of dp5 shows that
FGF and dp5 can only form 1:1 complex (FGFdp5) and there is no evidence
suggesting other stoichiometries are present. The CCS for the complex based on the
+7 charge state is 17.80 nm2 and this value is very close to that of unbound FGF at
17.50 nm2, suggesting that this minute CCS increment (+1.7%) is contributed by the
size of dp5 itself when it presents on the protein surface and does not induce major
conformational change of the protein.
Similar to unbound FGF, when (FGFdp5)+7 was treated with collisional
activation both protein unfolding and fragmentation were observed. However, we
also observed that an intense peak in the product ion spectra gradually shifted to
the lower m/z as the collisional energy increases, starting from the m/z value
corresponding to precursor (FGFdp5)+7, and finally stopped by the m/z value
corresponding to unbound FGF+7. This peak represents the FGFGAG complex
whose saccharide components are stripped from the complex successively and the
protein component still remains intact during this process. To examine how binding
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to dp5 or GAG fragments affects the protein unfolding pathway, we focused on a
population of FGFGAG (without taking any unbound FGF population) in each
spectrum for extraction of CIU fingerprint. It clearly shows that the energies for both
transitions are lower compared to those of unbound FGF+7 (Figure 4-3, B vs. C). We
can conclude that interaction with dp5 does not change the number of intermediate
states or significantly affect their conformations but it inhibits protein unfolding by
stabilizing individual states.
The correlation between the protein conformation and the mass loss were
studied based on average mass spectra scanned within ion-mobility arrival time of
each state individually. For the native state (Figure 4-4A, grey trace), the spectrum
under mild activation (350eV) displays a group of equally spaced peaks (∆m=22Da)
corresponding to the mass of FGFdp5 plus various number of sodium adducts. The
sodium ions are extensively attached onto dp5 molecule, observed in the spectrum
of dp5 alone (Figure 4-S1A). When the applied energy was increased to 490eV, two
more groups of peaks with 79Da less than the original group appear, indicating the
loss of sulfate groups. For the native states, we did not observe other reasons that
caused mass decreases rather than sulfate shedding. The mass spectra of the
complex in the partially activated state (Figure 4-4A, blue trace) are identical to
those in the native state against the applied energy under 560eV. When the applied
energy went above 560eV, the native population was completely converted to the
partially activated state; meanwhile some ionic signals appeared corresponding to
the gradual mass decrease in a larger interval than the one caused by sulfate
shedding. When the applied voltage is above 700eV, two distinct populations of
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fragment ions became apparent, one representing FGF with pentasaccharide
residues containing two sulfate groups (m/z ~ 2430) and the other with
trisaccharide residues (m/z ~ 2390). It suggests that the unbound saccharide units
can be removed from the FGF surface in the partially activated state through
glycosidic bond cleavage (Figure 4-4B, blue trace). In the fully unfolded state
(Figure 4-4B, red trace), GAG fragmentation occurred dramatically and an unbound
FGF peak (m/z = 2283) became dominant. These results demonstrate that as long as
the complex stays native or partially activated, the heparin-binding domain of FGF is
intact and the specific interactions including H-bonds formed between protein
residues and the sulfate or carboxyl groups on GAG are normally maintained. In the
fully

unfolded

conformation,

essential

protein

structural

features

for

accommodation of GAG ligand are lost and therefore the remaining saccharide units
can be rejected immediately. These results also suggest that “non-essential
segment” in the native state of the gaseous ion may be collapsed onto the protein
surface via long-distance electrostatic forces. These non-specific interactions play
important roles in stabilize the native conformation. In the partially activated state,
the structural features related to the non-specific interaction are disrupted and
therefore the non-essential segment happens to detach from the protein surface
after being cleavage.
The m/z values of the dominant peaks are plotted against applied energy for
all three states (Figure 4-5). As a negative control, unbound FGF+8 does not show
any collision-dependent mass decrease (Figure 4-5). The value of (FGFdp5)+7 in
the partially activated state (blue open dots) keeps decreasing and then remains
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unchanged at two values, corresponding to FGF plus dp5 with two sulfate groups
(5,2,0) and FGF plus dp3 (two uronic acids and one glucosamine) with two sulfate
groups (3,2,0), respectively. This latter represents the last GAG components that can
reside in FGF that is not fully unfolded and it is assumed to be the minimal segment
to achieve specific binding. Indeed, this number is very close to the predicted
binding segment (3,3,0) based on previously confirmed trisaccharide motif that is
directly involved in the interaction with FGF (Figure 4-1A).

4.3.3 Probing interaction between FGF and heterogeneous decasaccharide
We hypothesize that this established approach for identifying the binding
motif of heparin can generate a constant result no matter the heparinoid chain
length and heterogeneity. FGF was incubated with decasacharide (dp10) containing
diverse sulfation pattern, which was isolated from the native heparin degradation
products using size-exclusion chromatography, and was analyzed using native mass
spectrometry. The stoichiometry of the complex formed by FGF and dp10 cannot be
determined upon the acquired mass spectrum alone because the peaks are rather
broad and partially convoluted due to the intrinsic mass heterogeneity of dp10
(Figure 4-6A and Figure 4-S1B). Ion-mobility can considerably enhance the
confidence of charge state assignment for the reasons that (1) adjacent ions with
different charge can be fully resolved based on their drift time and (2) the CCSs for
all tentative charge states of the same specie are supposed to be constant. In order
to separate ions that have different charges but still overlap, for instance the
population at m/z 2700, a mild collisional voltage (50V) was applied to all ions and
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it was expected to make the overlapped ions distinguishable through differential
protein activation because the ion with higher charge actually bear higher
collisional energy. As a result, one series of ions, which are supposed to have higher
charge, readily shift into the region of the field with higher drift times. They
represent a ternary complex with two FGF molecules bridged by one dp10 chain
(FGF2dp10), which is consistent with previous observations15,16, while the
remaining series of ions that are relatively inert to activation represent the 1:1
complex (FGFdp10)(Figure 4-6B). The coexistence of two stoichiometries are
verified by a post-IM CID for the ionic populations at m/z=2700 (Figure 4-6C).
The 1:1 complex FGFdp10 at +7 and +8 were individually isolated and were
followed with stepwise increased collisional voltage. The complex shows the same
behaviors as FGFdp5 (Figure 4-S2 and Figure 4-S3). Briefly, GAG fragmentation
occurred with protein unfolding. In the presence of dp10, protein in the lower
charge state had the smallest transition energy between different folding states and
the mass loss of the complex in the partially activated state was much more gentle
compared to that in the fully unfolded state. Based on the mass loss profile of
(FGFdp10)+7 in the partially activated state, the energy threshold for removing
non-specifically attached saccharide units is about 95V (665eV), similar to the value
in FGFdp5 complex. However, the mass of GAG remaining in the protein complex
falls in the range corresponding to the tetrasaccharide (Figure 4-S4). We also
observed a peak at m/z 2664, representing the GAG-free FGF with +6 charge, when
collisional voltage was above 90V (630eV) and this charge-reduced product ion only
had one major population with a CCS value as small as the native protein. Therefore,
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it is very intriguing that the protein does not need to be fully unfolded in order to
release the remaining GAG-FGF interactions but it can be refolded to an even
smaller size only if one charge on the protein is stripped off by the leaving GAG.
However, this pathway is only found in (FGFdp10)+7 and the reason is still not
clear.
We also investigated the FGF2dp10 ions under collisional voltage. Contrary
to our expectation, prior to the energy reaching the threshold to trigger CID of
bound dp10, FGF2dp10 follows a typical pathway of collision-induced proteinprotein complex dissociation with asymmetric charge partitioning17: one protein
monomer is rapidly unfolded and released from remaining binary complex.
Therefore, this gas-phase approach may not be used for estimation of the binding
motif in a heparinoid-bridged ternary complex as long as the proteins directly
contact to each other.

4.4 Conclusions
This approach is a potential tool for estimating the number of sulfate and
saccharide units within the binding motif of GAG. As suggested from our FGF•dp5
data, FGF binding will afford the heparinoid segment protection from the collisioninduced saccharide degradation locally, while the segments not involved in the
interaction will be removed. However, the performance of this approach really
depends on the energy threshold for different effects induced by collision. In
general, shorter heparinoid chains required lower energy to achieve the last step,
where all unnecessary components of GAG are removed. A lower charge state
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should be chosen for CID to avoid malice protein unfolding; otherwise no
meaningful fragmentation data can be generated.
The protein unfolding intermediates can be easily monitored using IMS.
However this is not a strict approach that can reveal details of the protein structure.
Detailed simulations must be carried on in future, so we will know the location
where the unfolding happens. Nevertheless, the approach described in this chapter
allows us to monitor the status of the ions manipulated in the gas phase.
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Figure 4-1. Schematic of a gas-phase “top-down” approach to identify the
protein-binding of motif in unfractionated heparin
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Figure 4-2. (A) Native MS of FGF alone and in the presence of synthetic dp5. (2)
The GAG components involved in the FGF-binding (highlighted in purple) are
predicted based on the known binding motif identified in standard dp4
(within the brackets)
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Figure 4-3. CIU fingerprint graphs of (A) FGF+8, (B) FGF+7 and (C) FGF•dp5+7
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Figure 4-4. Fragmentation of FGF•dp5+7 induced in different unfolding states
(A) below 490 eV (70V) and (B) above 630 eV (90V).
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Figure 4-5. Plots of m/z value of survived FGF•GAG complex or FGF ions versus
applied activation energy.
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Figure 4-6. Characterization of FGF/dp10 complexes using IMS-MS: (A) mass
spectrum of FGF/dp10 mixture; (B) distinguish of overlapping populations
using pre-IM activation followed IMS-MS; (C) verification of the identities of
two populations with the same m/z using post-IM CID.
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Figure 4-S1. Mass spectra of (A) synthetic dp5 and (B) dp10 acquired in the
negative mode.
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Figure 4-S2. IMS-MS of FGF alone and in presence of dp10 under different
collisional voltage. Critical changes regarding the mass and conformation are
labeled on the graphs.

Figure 4-S3. CIU fingerprint for FGF•dp10 at +8 and +7 charge states
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Figure 4-S4. Monitoring the mass loss of FGF•dp10+7 at different collisional
voltage. The last survived complex is probed and compared with the one
deduced from FGF•dp5+7.
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CHAPTER 5
DEVELOPING A NOVEL PLATFORM BASED ON ENZYMATIC DEGRADATION AND
SIZE-EXCLUSION CHROMATOGRAPHY-MASS SPECTROMETRY FOR
IDENTIFYING PROTEIN-BINDING MOTIFS IN HEPARIN-LIKE
GLYCOSAMINOGLYCANS§

5.1 Introduction
Heparin-like glycosaminoglycan play crucial roles in regulation of diverse
functions. However deciphering the mechanisms of heparin-mediated regulation is
challenging due to the tremendous structural variety of heparin chains, defined by
modifications including O-sulfation, N-sulfation and N-deacetylation within a
disaccharide repetitive unit. The modification is controlled enzymatically by
mechanisms that are still unclear, which leads to combinatorial modification
patterns presented in naturally-occurring heparin-like GAG samples. In the last
chapter, we described a mass spectrometry-based approach to identify the minimal
binding motif of heparin (defined by the number of sulfate group and saccharide
unit within the interface), which utilizes a “top-down” idea to chop off the
unessential components (including GAG chains and the sulfate groups that are not
involved in the interaction) from a protein-heparin complex. Mass measurement of
the surviving complex indicates the minimal binder. However, as we have shown in
the last chapter, the gas-phase collision-induced fragmentation of GAG in a

§

The data reported in this chapter will be in a manuscript for publication.
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meaningful way is limited to a simple system consisting of PTM-free protein and the
heparin chain shorter than 10 saccharide units.
In this chapter, we introduce an alternative procedure in which the
degradation of GAG component is induced in a manner of enzymatic digestion.
Heparinase-based heparin degradation used to have a routine application to create
low-molecular-weight heparin1-3. We expected that heparinase would degrade every
disaccharide unit along the GAG chain gradually except in the region where the
client protein is interacting. In order to achieve this goal in an unbiased fashion, the
family II of heparinase is chosen from all candidates for the following advantages:
(1) it has the least preference to the cleavage site and can digest along the
polysaccharide chain in both sulfate-rich domain and neutral domain; (2) only two
saccharide units one each side of the scissile bond (P1 P2 | P1’ P2’) of GAG chain are
required for initiating the enzymatic recognition4,5 so that it can access the
saccharide adjacent to the region protected by client protein and “clean out” the
unbound components thoroughly. In pursuit of high performance of analysis, we
developed

an

online

size-exclusion

chromatography

(SEC)

native

mass

spectrometry (MS) platform, which embraces the benefits from the both techniques
(Figure 5-1A). It allows the surviving protein complex to be isolated from the
degraded GAG products and to subject to a real-time ion detection by MS. Native MS
has been successfully used for sorting the binders from a combinatorial
oligosaccharide complex upon the affinity to a protein6. Based on our previous
experience, the performance of native MS including resolution and dynamic range
for detection in a heterogeneous sample can be significantly improved vis-à-vis the
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incorporation of online chromatography7. And the elution profile for individual
species can be extracted and it allows us to monitor the dynamic impact on each
other8. In addition, although the digestion is carried on in the solution phase, we can
still take advantage of the gas-phase chemistry to get rid of the unessential sulfate in
the protein-interacting domain, which cannot be removed in the step of heparinase
treatment.
In this work, we test this approach for the binding motif for antithrombin,
which has been well established (Figure 5-1B) in previous studies9,10, in the
complex with heparin oligosaccharide with 20 units.

5.2 Experimental
Antithrombin-III (AT) dominantly consisting of the α-form (with four
glycosylation chains) was purchased from Haematologic Technologies (Essex
Junction, VT). Heparin oligosaccharide dp20 was purchased from Iduron (UK). In
order to form a strong complex, AT and dp20 were incubated in 1:5 molar ratio at
room temperature for 30 min in the solution containing 30mM ammonium acetate
at pH 7. Heparinase II was added into the mixture to a final concentration 8 u/ml
and incubated for another 30min at 35 degree. The sample was immediately
transferred in to a sample vial and ready for SEC-MS analysis.
The platform of SEC-native MS is shown in Figure 5-2A. Chromatography is
carried on in Agilent 1100 equipped with autosampling system. The flow rate for
SEC (TSK G3000) separation is set to 0.3 ml/min. A fluid splitter was employed to
reduce the flow prior to injection to the source of Bruker SolariX FT-ICR mass
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spectrometer (Billerica, MA). In source CID voltage was set to 60V. Sample injection
and data acquisition was triggered from computer using Hystar software. GAGligand can be dissociated from the protein complex by mixing with methanol
solution containing 12% acidic acid. The solution was pumped into a fluid mixture
by another HPLC at the same flow rate (0.3 ml/min), where the SEC fluid was mixed
with the denaturing solution allowing the protein complex to be denatured and
release the GAG ligand. The released GAG was then subjected to the mass
spectrometer for an accurate mass measurement (Figure 5-2B). Online LC-MS data
was processed using DataAnalysis software.

5.3 Results and Discussion
5.3.1 SEC-native MS analysis of the heparinase-digested products of AT•dp20
complex
The digestion mixture passed through SEC column with two major retention
times displayed on the UV trace (Figure 5-3A, grey trace). The early peak (eluted at
19-22min) represents the protein-GAG protein mixture and the late peak (eluted at
28-30min) represents the pieces of disaccharide degraded from the intact GAG
chain. There are some early-eluted species with very low UV absorbance (2528min) corresponding to the GAG components with longer polysaccharide chain
produced by incomplete digestion. The Base Peak Chromatogram (BPC) reflects the
time when ionic signal was actually detected by MS and it shows an obvious delay
(~2 min) compared to the UV profile. Upon the BPC profile, the average mass
spectra within three continuous time windows in the early major peak are shown in
Figure 5-3B. We clearly saw that during such a short period less than 1.5 min, three
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species were eluted one after another and successfully detected by MS. The first
spectrum represents AT•dp20, and perhaps other unresolved species. The second
spectrum displays many peaks corresponding to the complexes formed by AT and
GAG with different mass ranging from dp6 to dp10. They were produced from the
partial digestion of GAG in the presence of AT. The third spectrum is only comprised
of the GAG-free AT. We did not observe any AT-involved complex that contains less
than 6 saccharide units during any period of elution. The order of the peak elution
also agrees with chain length of the GAG binding to the protein.
Based on the spectrum with +16 ions of AT in complex with short chain
oligosaccharide (i.e. AT•dp6+16, AT•dp8+16, AT•dp10+16), only one sharp and
abundant peak was observed for each complex (see Figure 5-3C for a zoom-in
view), corresponding to (6,6,1), (8,9,1) and (10,12,1) respectively. (In the standard
nomenclature system of GAG, (X,Y,Z) represents the structure in terms of the
number of saccharide (X), the number of sulfate groups (Y) and the number of
acetylation groups (Z).) These numbers indicate the specific modification pattern
that plays the most important roles in AT-binding. Mass accuracy of our
measurement is shown in Table 5-1. The binders with other patterns either leave
from the protein in the early stage or have the unessential sulfate groups to be shed
in the gas-phase during in-source CID. The elution profiles extracted for the three
peaks indicate that AT•(6,6,1) is the most abundant complex that survived from
heparinase treatment and in-source purging (Figure 5-3D). It is well known that AT
can specifically interact with a piece of GAG containing a pentamer (5,6,1). Although
additional sulfate groups and saccharide units may also enhance the binding affinity,
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the six sulfates presented in Figure 5-1B are most important and represent the
minimal requirement to trigger strong and specific interaction, which has also been
demonstrated in a crystal structure. Our results are highly consistent with what
have been identified previously in terms of the numeric modification pattern. In our
harsh condition, all unessential sulfate groups are shed, even some of those that may
contribute to the specific or non-specific interactions. As a conclusion, the binder for
a protein can be determined in a one-step measurement with high mass accuracy;
while the traditional ways to identify the binder of strong affinity is very timeconsuming.

5.3.2 Identification of the GAG ligand through online protein denaturation
Measuring the mass of intact complex using native MS is promising however
the lack of the isotopic peaks for a highly charged ion of protein-GAG complex (e.g.
AT•(6,6,1)+16 in Figure 3C) probably leads to inaccurate mass measurements. For
this reason, we designed an experimental setup (illustrated in Figure 5-2B) that is
able to dissociate the remaining minimal binder from the protein complex via an
online denaturing. It allows the binder itself to be measured using FT-MS, which
gives more accurate results compared to the measurement of non-covalent complex
using native MS. First, we test whether a protein can undergo unfolding by mixing
with the denaturing solution after the native protein is from SEC column. The mass
spectra for the SEC peaks of BSA are shown in Figure 5-S1, where the low m/z of
charge envelops of both monomeric and dimeric BSA apparently indicates that the
protein has an unfolded conformation during electrospray. Then we tested whether
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the unfolded AT can release a small GAG ligand, ArixtraTm (5,8,0). It is a synthetic
mimic of the pentameric binder with the same modification pattern, except for an
additional sulfate group replacing the acetylation group in the naturally-occurring
binder (5,6,1) or (5,7,1). The UV trace of the chromatogram is identical to the one
without mixing with denaturant because the denaturation step occurs after UV
detection. Only one peak is visible in the chromatogram, characterized by the
AT•Arixtra complex according to its retention time (Figure 5-4A, grey trace). The
identity of this peak is also verified based on the native mass spectra (Figure 5-4B,
green trace), in which no free AT is observed. In contrast, no AT•Arixtra is survived
in denatured MS (Figure 5-4B, blue trace), suggesting that the ligand is dissociated
from the complex. During the sample preparation, Arixtra was added in excess to
the sample so there is another peak eluted at ~25 min corresponding to the excess
Arixtra, which cannot be seen in UV trace because Arixtra does not have UV
absorption. The mass spectrum of Arixtra was acquired in the negative mode in
order to reach the best sensitivity, in which the isotopic peaks of Arixtra can be
clearly observed (Figure 5-4B, orange trace). Extracted ion chromatogram for
Arixtra display two peaks (Figure 5-4A, orange trace), one (at ~25 min)
representing the excess fraction not involved in the interaction with AT and another
(at ~20 min) representing the fraction in AT•Arixtra complex as an attached ligand.
Therefore, we can probe the identity of GAG ligands within the same time window
when the protein complex is eluted using this online denaturing approach.
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5.4 Conclusions
The existence of unbound AT suggests that there is a competition between
AT and heparinase in terms of the binding affinity to heparin chains. Generally, for
an enzyme, a higher substrate turnover rate will make the affinity for the substrate
weaker (KM), therefore heparinase digestion should be carried out under conditions
where the enzyme has highest turnover rate, in order to avoid stripping the GAG
chain off from the surface of AT. We described in the previous chapter, non-specific
electrostatic interaction is remarkable in the gas-phase and likely to force the entire
heparin chain to collapse on the surface of the protein, which prevent the saccharide
with weak interaction from being removed. In the solution phase, this accessibility
issue has been circumstance. Our data strongly suggest that the regions of dp20 that
does not contribute to the strong interaction can be accessed by heparinase for
cleavage.
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Figure 5-1 (A) Workflow of approach based on enzymatic degradation to
identify the minimal protein-binding motif for heparin-like GAG. (B)
Previously identified minimal binding segment for antithrombin-III; the
critical
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Figure 5-2. Schematics of (A) SEC-native MS and (B) SEC-denatured MS.
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Figure 5-3. SEC-MS of heparinase-treated AT-dp20 complex (A) SEC profile of
heparinase-treated AT-dp20 complex. (B) The average mass spectra for
different retention times at T1: 20.4-20.8 min; T2: 20.8-21.2 min; T3: 21.221.6 min. (C) Zoom-in view of the mass spectrum for T2. (D) Elution profile for
four species detected by SEC-MS.
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Figure 5-4. Online SEC-denatured MS tested with the AT-Arixtra complex: (A)
UV trace (grey) and extracted ion profile of AT (blue) and Arixtra (orange)
extracted based on the peaks in denatured MS. (B) Average mass spectrum
under native condition (green) and denatured condition (blue) within the
chromatogram peak at T1 and under denatured condition with the
chromatogram peak at T2 (orange).
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Figure 5-S1. Online SEC-denatured MS of BSA: (A) UV and BPC traces of SEC
chromatogram of BSA, dimer and monomer peaks are indicated with arrows;
(B) average mass spectra of BSA dimer (top) and monomer (bottom) under
denatured condition (blue) and monomer under native condition (green).

Table 5-1. The measured mass and calculated average molecular weight at
major peaks in SEC-MS of AT•dp20 degraded complex
Unit: Da

(6,6,1)

(8,9,1)

(10,12,1)

measured
calculated

1534.4
1534.2

2111.4
2111.7

2689.3
2689.1
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CHAPTER 6
SUMMARY AND FUTURE DIRECTIONS

6.1 Summary
Heparinoid molecules bind to heparin-binding proteins through both the
long-distance electrostatic attraction between opposite charges and the shortdistance interactions including hydrogen bonding and salt-bridge bond. Native MS is
an excellent tool to probe these non-covalent interactions. We developed multiple
strategies particularly for this system based on the special properties of heparinprotein complexes. First, protein and heparin bind more tightly when they are
introduced to the gas phase, so we can take advantage of the strong electrostatic
interaction to carry out lossless ion manipulations in the gas phase. For examples,
we selectively chopped off the unbound GAG component using collision-induced
activation for identifying the number of saccharides and sulfate groups that reside
on the binding interface (Chapter 4); and we also performed limited charge
reduction to reconstruct the mass and charge values for protein-heparin complex
ions whose binding stoichiometry does not change during reaction with the electron
donors (Chapter 2 and 3). Second, the structure of gaseous ions introduced by
native electrospray is largely similar to that in the solution and allow us to study the
conformation of protein complex in the gas-phase using IM-MS. With CCS
measurement, for examples, we were able to capture a near native structure of FGFoligosaccharide complex and other two intermediate states created by collisioninduced unfolding (Chapter 4); and we also observed two distinct models for
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protamine-oligosaccharide complexes (Chapter 3) based on the charge-reduced
populations. Third, the presence of GAG chains brings about high degree of
heterogeneity in the complexes and it triggers the development of “top-down”
strategies to fetch the unique elements contributed to the binding affinity.
Technically, to reduce the heterogeneity, we built multiple two-dimensional
platforms by incorporating a separation tool with MS detection such as quadruple
isolation (Chapter 2 and 3), online chromatography (Chapter 5) and ion-mobility
separation (Chapter 2,3,4).
It should be noted that all strategies we describe in previous chapters are not
limited to the system of heparin-protein complexes; it has potential to be applied to
other analytes with polydispersed mass distribution. Online SEC-MS and IXC-MS are
powerful tools for quantitatively analysis of non-covalent protein-protein
complexes with multiple stoichiometries such as the complexes formed by
monoclonal antibody and antigens or Fc receptors. Limited charge reduction can be
used for interpreting unresolved spectra (MS or IM-MS) of samples containing
proteins with heterogeneous modifications (e.g. antibody drug conjugation,
PEGylated proteins). Our results in Chapter 2 through Chapter 5 provide valuable
data and examples showing how those strategies can work as novel solutions to the
heterogeneity-related problems.

6.2 Future directions
Beyond my dissertation studies described in previous chapters, there are
three major directions we can explore in the future. Because CCS is an average
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projection area of a molecule at all orientations, it can reflect anisotropy to some
extent. As a result, the measured CCS values for a protein (e.g. FGF, AT and
protamine) in the presence of GAG chain are correlated to the structure of the
gaseous ions. However the specific structure of a protein complex is still not clear. In
future, we will perform molecular dynamic (MD) programs such as GROMAC, VMD
to simulate the structures during protein aggregation or protein unfolding under
collisional activation over a period of time. We will also extract CCS values from
several snapshots obtained from MD and find the one that is closest to the
experimental CCS. This approach can eventually help us to understand what domain
of FGF is unfolded in the partially activated state and to confirm that the binding
interface is not damaged in this state.
In Chapter 4 and 5, we only focus on identifying the binding motif on
heparinoid chain. We are also interested in mapping the heparin-binding epitope on
the protein using MS-based footprinting such as hydrogen/deuterium exchange
(HDX), covalent labeling or cross-linking. HDX-MS has been a well-established
technique to probe the protein-ligand interface assuming the ligand can change the
solvent-exposed surface of the protein. We hypothesize that the region of protein
that binds to heparin is less solvent-exposed in the presence of heparin and shows a
lower deuterium uptake. This approach has never been reported by others so we
can test it with well-studied heparin-binding proteins such as FGF and AT.
At last, as shown in Chapter 5, the degradation of heparin using heparinase
allows us to generate the minimal segment of GAG that is bound to AT. We also
demonstrate that analyzing the saccharide units dissociated from the complex
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through protein denaturation can achieve better mass accuracy compared to
analyzing the mass of AT•GAG complex using native MS; the latter requires higher
mass range and more delicate desolvation condition. In future, we will develop an
approach to achieve this goal with higher controllability. First, we will immobilize
the protein on beads and pack them into a preparation column. Then we will load a
mixture of heparinoid molecules and wash with the equilibration buffer. Next, we
will wash the column with the solution containing proper concentration of salt to
get rid of the nonspecifically bound species. Heparinase digestion step will be
carried out by directly injecting the enzyme into the column and leave at 33°C for
adequate time. Then we will wash out the degraded unbound products with the
washing buffer and elute the tightly bound species by increasing the concentration
of salt in the mobile phase. The eluted fraction can be analyzed using FT-MS after
desalting and lyophilizing the sample. We can test this approach with AT because
immobilized AT is a matured technique for screening heparin fraction with high
anticoagulant effect. The in-column digestion is also a routine approach that has
been performed in the process of GST-fusion protein purification. Therefore we
assume that this approach we propose here is feasible and may give us some results
with higher accuracy and less bias.
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APPENDIX
CCS CALIBRATION CURVES
CCS calibration was carried out following the standard protocol that can be
found in Nature Protocols 3, 1139 - 1152 (2008). The curves are plotted using
reported CCS of standard proteins (y-axis) vs. the corrected drift time measured in
the experimental condition (t”, x-axis).
Standard proteins were selected based on the required mass range of the
sample to be analyzed. For the protamine-do20 experiment (see Chapter3), the
standard proteins are Cytochrome C and monomeric β-Lactoglobulin. For the
FGF•dp5/dp10 experiments the standard proteins are Cytochrome C, βLactoglobulin, BSA and ADH. All standard proteins were analysis under native
conditions.
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Figure APPX-1. CCS calibration curves for protamine-dp20 experiment
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